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PREFACE 
When I commenced clinical practice as an endocrinologist in Tasmania during the mid-
1990s, I was intrigued by reports from a number of jurisdictions of an increasing 
incidence of papillary thyroid carcinoma (PTC). Varying causes had been proposed. 
Spurious methodological factors such as improving case registration by Cancer 
Registries, changes in the morphological classification of thyroid tumours and finer 
sectioning of thyroidectomy samples were postulated. Similarly, a true change in PTC 
incidence due to increased exposure to risk factors such as ionising radiation and changes 
in iodine nutrition were also proposed as explanatory. 
Tasmania is an island State of the Australian Commonwealth with a stable population 
structure, sophisticated medical infrastructure and a well characterised history of iodine 
deficiency. This presented the opportunity for using the Tasmanian population as a 
model to evaluate the cause of observed PTC incidence trends. 
The research presented in this thesis was undertaken by myself between 1995 and 2006 
in an attempt to answer fundamental questions regarding incidence trends for PTC - 
namely, has there been a true increase in the incidence of PTC and if so, what factors 
underlie this change? My role encompassed conceptual planning, the development and 
submission of applications for funding, preparation of documents for Institutional Ethics 
Committee approval, patient recruitment, database construction, statistical analysis, and 
preparation of manuscripts for publication. Candidature for this PhD was approved and 
undertaken in keeping with the provisions of Appendices A.4 and A.5 — previously 
published research. 
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STATEMENT OF THE PROBLEM 
Papillary thyroid carcinoma (PTC) is the most frequently diagnosed endocrine 
malignancy. Cancer registries in many countries have identified a substantial increase in 
the reported incidence of PTC over the past half-century. The explanation for this 
remains to be elucidated. 
Improved PTC case ascertainment by cancer registries, heightened histopathological 
recognition of small and subclinically PTC, increased use of neck ultrasonography and 
greater recourse to fine needle aspiration biopsy in evaluation of thyroid nodules may be 
contributory. An increase in the underlying occurrence of PTC is also possible, with 
exposure in childhood to ionizing radiation as well as changing levels of iodine nutrition 
potential underlying factors. 
In this thesis I sought to answer the following questions: 
1 	Has the incidence of PTC increased in Australia? 
2 	Is there evidence of geographic variation in PTC incidence within Australia? 
3 	Is the Tasmanian population a suitable model for evaluating the basis for 
Australian PTC incidence trends? 
4 	Are changes in observed PTC incidence due to changes in histopathological 
diagnostic criteria or Cancer Registry case ascertainment? 
5 	What is the contribution of increased diagnosis of microscopic and clinically 
"occult" PTC to observed incidence trends? 
xi 
6 	Are geographic patterns of PTC incidence related to the historical or 
contemporary distribution of iodine deficiency in Australia? 
7 	Does iodine nutrition influence the PTC incidence by either altering tumour 
pathogenesis or by indirectly increasing the likelihood of diagnosing "occult" 
PTC? 
8 	Is there evidence for past exposure to ionising radiation as an aetiological 
driver for contemporary PTC incidence? 
9 	Is there evidence for heritable susceptibility to PTC influencing observed 
incidence trends? 
10 	Is it possible to estimate the relative contributions of ascertainment bias and 
changes to the underlying biological incidence in producing contemporary 
PTC incidence trends? 
xii 
AIMS 
1. To assess temporal trends for thyroid carcinoma in Australia and determine if 
PTC incidence has increased. 
2. To determine the validity of the Tasmanian population as a model for 
understanding PTC incidence trends both in Australia and internationally. 
3. To determine the contribution of non-biological factors (changes in 
morphological classification, Cancer Registry ascertainment and alterations in 
clinical practice paradigms) in shaping PTC incidence trends. 
4. To determine the contribution of both established and putative PTC risk 
factors (ionising radiation, genetic susceptibility and iodine nutrition) in 
shaping PTC incidence trends. 
HYPOTHESIS 
1. The Tasmanian community provides a population model for investigating 
national incidence trends for PTC. 
2. Non-biological factors (bias due to alterations in medical practice and data 
management systems) account for the majority of the apparent rise in PTC 
incidence observed over recent decades. 
3. A true increase in underlying PTC incidence accounts for a small, but important 
component of observed PTC incidence trends. 
xiv 
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ABSTRACT 
Thyroid carcinoma (TC) is the most prevalent endocrine malignancy. Four main sub-
types are recognised - papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, 
medullary thyroid carcinoma and anaplastic thyroid carcinoma. PTC accounts the 
majority of diagnoses. As is typical of most thyroid disorders, women are affected 
approximately four times more frequently than men. The absolute incidence of PTC 
varies significantly between geographic locations and racial groups, suggesting an 
important interaction between environmental and genetic risk factors. 
Aside from relative differences in absolute PTC incidence between different 
communities, a significant increase in PTC incidence has also been observed within 
many populations over recent decades. In some jurisdictions the incidence of PTC has 
increased more than two fold. Industrialised as well as developing nations have been 
affected. Possible explanations include artifact due to changes in both medical practice 
and tumour registration by Cancer Registries. However, a true biological change in PTC 
pathogenesis and incidence is also possible. Family history and exposure to ionizing 
radiation are the most clearly established risk factors. Iodine nutrition may also influence 
the risk of thyroid malignancy, both by modulating thyroidal radioiodine uptake as well 
as by directly influencing the pathogenesis of benign and malignant thyroid disease. 
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My research reviewed Australian national TC incidence trends during the 1980's and 
1990's, identifying a rise of between 4.0% and 24.7% per annum in the incidence of PTC 
across the Australian states. This rise was most obvious in the eastern seaboard states, 
mapping to those states with the lowest historical levels of iodine nutrition. The greatest 
rise in PTC incidence was observed in Tasmania, an island State of the Australian 
Commonwealth, where PTC incidence increased by 24.7% per annum. Tasmania has a 
well-characterised history of iodine deficiency and a stable demographic structure with a 
centralised health care system and established Cancer Registry. These characteristics 
provided an opportunity for evaluating in detail the basis for the more widely observed 
rise in PTC incidence. 
A detailed evaluation of Tasmanian Cancer Registry data over the 21-year period 1978- 
'98, confirmed that the incidence of PTC had increased by 450% in females and 210% in 
males. Furthermore, validation of Cancer Registry case ascertainment by de novo 
reconstruction of a Tasmanian TC data-set (using source pathology and hospital 
documentation), confirmed 93.9% completeness for existing PTC case ascertainment by 
the Cancer Registry over the study period. Similarly, a review of histopathological 
diagnoses did not demonstrate any significant change in the morphological classification 
of TC during this time. These findings exclude changes in either case reporting or 
tumour classification as the primary cause for observed PTC incidence trends. 
The key trend underlying observed changes in PTC incidence was an increase in 
diagnosis of small (<1cm) PTC that were asymptomatic at the time of resection. 
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Further studies evaluated the prevalence of both clinical and subclinical (by 
ultrasonography) nodular thyroid disease in the Tasmanian population. Thyroid 
ultrasonography revealed nodules in 43.4% of individuals evaluated, the majority (88%) 
of whom had no previously recognised history of thyroid disease. Non-specific neck 
imaging therefore had the potential to identify clinically inapparent thyroid nodules. 
Contemporary evaluation protocols for asymptomatic and incidentally discovered thyroid 
nodules promote the use of fine needle aspiration biopsy (FNAB) and specimen cytology. 
An assessment of trends for utilization of thyroid FNAB identified an increase of 17.6% 
per annum and 66.2% per annum for males and females respectively during the period 
1988- 98. As the prevalence of clinically silent PTC .1cm diameter ("occult" PTC) is 
reported to be approximately_ 5% in thyroid nodules, contemporary patterns of neck 
imaging and the subsequent FNAB evaluation of subclinical thyroid nodules might 
explain much of the recently observed rise in incidence of PTC. 
I further evaluated the relationship between iodine nutrition and PTC incidence. 
Comparison of documented changes in iodine nutrition in Tasmania during the past five 
decades against observed PTC incidence trends showed the increase in PTC incidence 
occurred during a period when the Tasmanian population was undergoing transition from 
iodine sufficiency to mild iodine deficiency (after the almost 30 years of optimal iodine 
nutrition that followed correction of endemic iodine deficiency in the mid-1960's). This 
observation was unexpected given much of the existing epidemiological evidence links 
poor iodine nutrition to a reduced proportion of PTC relative to other thyroid 
malignancies, and a lower incidence of PTC compared to iodine replete populations. 
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A study was undertaken to evaluate the impact of Tasmania (historically the most iodine 
deficient Australian state and the region with the greatest contemporary rise in PTC 
incidence) as a place of birth and residence, on the likelihood of developing benign and 
malignant thyroid disease. There was a significant association for goitre and 
thyroidectomy with childhood lived in Tasmania. The association was non-significant 
for the development of TC. Therefore, increased PTC incidence in Tasmania is 
potentially explicable on the basis of greater diagnosis of "occult" PTC, most probably 
diagnosed at the time of investigation and management of benign iodine deficiency 
related thyroid disease. 
I also identified evidence to suggest an increase in the underlying incidence of clinically 
relevant PTC. Analysis of Tasmanian cancer registry data confirmed a 260% increase in 
large (>2.0cm) PTC between 1978 and 1998. Moreover, it was notable that despite the 
rise in incidence of PTC versus FTC, changes in two-, five- and ten- year mortality rates 
for PTC remained parallel to those of FTC during the study period. As "occult" PTC 
usually exhibit a benign natural history, an increase in PTC incidence solely due to 
greater recognition of "occult" PTC would be expected to produce a disproportionate 
improvement in survival for patients with PTC relative to FTC. 
Ionizing irradiation of thyroid tissue in childhood is the best characterized aetiologic 
factor for thyroid neoplasia. Both benign and malignant tumours are predisposed, with 
PTC the most frequent malignant sequela. Studies suggest PTC arising after long latency 
following thyroid irradiation may exhibit a mutation (the RET/PTC1 rearrangement) with 
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a prevalence higher than for PTC from non-irradiated populations. In the absence of 
objective radiation exposure data, I attempted to use the RET/PTC1 mutation as surrogate 
marker for past exposure to ionizing radiation. Tasmanian PTC diagnosed between 1978 
and 1998 were studied to determine the temporal trends for prevalence of RET/PTC1. 
However, a clear relationship between PTC incidence trends and RET/PTC1 prevalence 
was not found. Despite this, it was notable that the absolute prevalence of the RET/PTC1 
rearrangement in Tasmanian PTC was greater than expected and was consistent with the 
prevalence in irradiated populations. Moreover, a significant clinicopathological 
association for the RET/PTC1 rearrangement was identified. Tumours positive for the 
RET/PTC1 rearrangement were of larger size and more likely to exhibit lymph node 
metastases than those without the mutation. 
The role of heritable susceptibility to PTC and the potential for a founder effect 
influencing Tasmanian PTC incidence trends was also assessed. A family history of TC 
was described by 14.1% of Tasmanian patients diagnosed with PTC. Two large PTC 
kindreds demonstrating an autosomal dominant inheritance pattern for PTC accounted 
for the majority of familial cases. However, the absolute contribution of autosomal 
dominant PTC to overall statewide incidence trends was small. A founder effect did not 
explain PTC incidence patterns in Tasmania. 
The research I have undertaken provides a useful insight into the genesis of Australian 
national PTC incidence trends. Whilst there is evidence to support a small increase in 
the underlying incidence of clinically relevant PTC, the main cause for the observed rise 
in PTC incidence can be attributed to increased ascertainment of "occult" papillary 
5 
microcarcinoma. The findings of my research highlight the potential adverse health 
consequences of inappropriate neck imaging and reinforce the importance of appropriate 
education for medical practitioners regarding the rational use of thyroid ultrasonography. 
6 
CHAPTER 1 
Background Literature 
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THYROID ANATOMY AND PHYSIOLOGY 
Anatomy and Embryology 
The thyroid gland comprises two lobes and an isthmus. Each lobe is approximately 4cm 
in length, 2cm in width and 2cm in thickness with a vascular supply derived from the 
superior thyroid artery and the inferior thyroid artery(1, 2). On microscopy, the thyroid is 
composed of follicles fed by an extensive capillary network. Each follicle comprises a 
single sheet of follicular cells (thyrocytes) surrounding a colloid filled lumen. Follicles 
are arranged in bundles separated by septae of connective tissue. Contained within the 
connective tissue surrounding the thyroid follicles are the parafollicular C cells that 
produce calcitonin(1-3). 
The thyroid is first evident embryologically at approximately one month post conception 
as a thickening of the pharyngeal epithelium, subsequently forming a diverticulum from 
the pharyngeal floor that fuses with the ventral aspect of the fourth pharyngeal pouch (1- 
3). Thyroglobulin (TG) begins to be synthesized during the second month of gestation 
and the ability to concentrate iodine is evident by the end of the first trimester. The fetal 
pituitary synthesizes thyroid stimulating hormone (TSH) early in the second trimester and 
thereafter both maternal and fetal thyroid hormones contribute to fetal hormone 
requirements (2-5). 
Thyroid Hormone Synthesis 
Iodine is an essential substrate for thyroid hormone synthesis(2, 6, 7). Inorganic iodide is 
concentrated by the thyroid via an energy dependent sodium iodide symporter(8-10). 
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Iodine is organically bound to thyroglobulin by a reaction involving thyroid peroxidase, 
which catalyses the iodination of tyrosyl residues of thyroglobulin to produce 
iodotyrosines(7). The iodotyrosines are subsequently coupled to produce the active 
iodothyronines, tetra-iodothyronine (T 4) and tri-iodothyronine (T3). T el and T3 remain 
bound within the thyroglobulin by peptide linkages until cleaved from thyroglobulin by 
proteolysis (2). 
TSH receptor activation drives thyroid hormone synthesis at various levels including 
active transport of iodine into the thyrocyte, synthesis of thyroglobulin, proteolysis of 
colloid and release of active thyroid hormones into circulation(1, 2, 7, 8). The secretion 
of TSH is mediated by hypothalamic release of thyrotropin releasing hormone (TRH), 
that in turn is regulated by central receptors located in both the hypothalamus and 
pituitary, which are sensitive to circulating thyroid hormone levels(1, 11, 12). TSH also 
provides trophic stimulus for growth and replication of the thyroid follicular cells. 
Iodine Nutrition 
A minimum of 100mcg of elemental iodine is required per day to prevent the 
development of iodine deficiency (13, 14). Both inorganic and organically bound iodine 
are ultimately absorbed from the gastrointestinal tract and small quantities are lost in 
through the skin and stool. Most iodine, however, is rapidly taken up by the thyroid or 
cleared via the kidneys(2, 10, 15). Renal iodine clearance is determined by glomerular 
filtration rate, uninfluenced by active processes (1, 15). 
There is marked variation in dietary iodine intake both within and between human 
populations (16-18). Whist dietary customs such as the routine consumption of seaweed 
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and other iodine rich foodstuffs are important, in most circumstances iodine intake is 
predominantly determined by the underlying geology of a community's geographic 
location. Up to one third of the world's population live in regions that contain borderline 
deficient levels of soil and water iodine(16, 18, 19). The water and foods derived from 
geologically deficient regions consequently contain insufficient levels of iodine to sustain 
normal thyroid function (2, 14, 16, 20). 
A diet deficient in iodine produces a variable spectrum of disease, influenced by both the 
degree of iodine deficiency as well as secondary genetic and environmental factors(21- 
23). The broad spectrum of derangement resulting from iodine deficiency has led to the 
use of the term Iodine Deficiency Disorders (IDD) (2, 6, 13, 24-26). Whilst goitre is the 
most characteristic and physically evident abnormality associated with iodine deficiency, 
other consequences include variable degrees of intellectual and neurological impairment, 
altered reproductive function and modulation of risk for autoimmune thyroid disease and 
thyroid neoplasia (2, 6, 13, 24-34). 
THYROID DISEASE 
General 
The spectrum of thyroid disease includes both structural and functional thyroid 
anomalies(35-37). The most frequently encountered derangements are diffuse thyroid 
enlargement, nodular thyroid disease, hyperthyroidism, hypothyroidism and thyroid 
malignancy. The aetiology of thyroid disease typically stems from abnormal iodine 
nutrition, autoimmune disease and neoplasia(1, 2). 
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Hypothyroidism 
Hypothyroidism can arise as either primary thyroid dysfunction or as a secondary 
abnormality involving the hypothalamus or pituitary(36). Primary hypothyroidism due to 
autoimmune disease accounts for the vast majority of cases. Autoimmune (Hashimoto's) 
thyroiditis is a chronic autoimmune condition associated with raised levels of anti-
thyroid peroxidase(2, 36). The overall community prevalence is approximately 2%, and 
like many thyroid disorders, women are more frequently affected than males (38, 39). 
Thyroid hypofunction is manifest as a spectrum from mildly raised TSH in the presence 
of a normal free thyroxine through to clinically overt hypothyroidism with an elevated 
TSH concentration and reduced peripheral thyroid hormone levels(40). The most 
reliable predictive factors for determining those individuals who will progress to overt 
hypothyroidism is the thyroid peroxidase antibody status and the level of TSH(35, 41). 
Patients frequently present with insidious onset of lethargy, weight gain and a range of 
other non-specific symptoms. Replacement of thyroid hormone with synthetic thyroxine 
is the standard therapy for this condition(1, 2, 42-44). 
Hyperthyroidism 
As is the case for hypothyroidism, hyperthyroidism is a pathologically heterogeneous 
entity unified by the primary abnormality of excessive thyroid hormone levels(37). The 
population prevalence varies with iodine intake, but is in the order of 0.5-2 % and as with 
other thyroid disorders, women are approximately 5 fold more frequently affected than 
males(37, 39). In young and middle-aged women autoimmune thyroid disease (Graves' 
disease) due to a stimulatory autoantibody capable of activating the TSH receptor is the 
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most common cause(37). In older individuals, particularly those residing in iodine 
deficient areas, autonomously functioning (toxic) thyroid nodules are frequently the 
cause (24, 45, 46). Rarely, excessive stimulation of the thyroid by inappropriate TSH 
hypersecretion, ectopic thyroid tissue (such as struma ovarii) and acute thyroid 
inflammation are the cause of hyperthyroidism(37). 
Iodine Deficiency and Benign Thyroid Disease 
The clinical presentation of thyroid dysfunction is modulated by the iodine nutritional 
status of the population studied(24, 47, 48). Laurberg et al have shown that in 
comparison with the relatively iodine sufficient population of Iceland, a mild to 
moderately iodine deficient population in Jutland demonstrated a later onset of Graves' 
disease, a lower rate of autoimmune hypothyroidism and a high frequency of 
hyperthyroidism in older individuals due to autonomous (toxic) multinodular goitre(25, 
48). Iodine nutrition therefore appears to influence not only the evolution of structural 
thyroid disease, but also the development and expression of autoimmune thyroid 
disease(22, 23, 47). 
The evolution of thyroid disease in the setting of iodine deficiency is a gradual process 
determined not only by the severity of iodine deficiency, but also by a range of 
constitutional factors such as genetic susceptibility(21, 46). Early in the pathogenesis of 
iodine deficient goitre, thyrocyte hypertrophy and hyperplasia occurs even within the 
context of TSH and FT4 levels which typically remain within bounds of the reference 
range(21, 46). Over time, non-toxic, diffuse goitre develop nodular elements. In the early 
stages of nodular evolution, hyperplastic expansion occurs, and in some areas thyroid 
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nodularity supervenes due to both polyclonal and monoclonal expansion by sequential 
acquisition of somatic mutations (46). Micro-heterogeneity of thyrocyte structure and 
function can progress by way of these acquired mutations of genes encoding growth and 
functional regulatory proteins, such as those for the TSH receptor and Gsa subunit 
stimulation of adenylyl cyclase(46, 49). Ultimately, such nodules acquire functional 
autonomy, the majority (60-70%) of which are monoclonal in origin (21, 46). 
A goitre may be defined as an abnormal enlargement of the thyroid gland(1, 2, 50). 
Whilst the exact volumetric criteria for defining goitre varies between authors, volumes 
greater than 13 -18m1 in adult females and 18 -25ml in males have been proposed, with 
an age or body surface area criteria for defining goitre in children(2, 51, 52). Whilst 
early studies of goiter prevalence used clinical evidence of thyroid enlargement (either 
visible or palpable thyromegaly), contemporary methods using ultrasonographic 
assessment allow identification of lesser degrees of subclinical thyromegaly(24, 50, 53). 
Ultrasounographic assessment is now central to the definition of goitre, which despite 
important operator-dependent variability, permits detailed assessment of internal thyroid 
architecture and measurement of overall thyroid dimensions for calculation of thyroid 
volume(51, 53). 
Simple goitre (non-toxic goitre) is defined as thyroid enlargement not associated with 
thyroid dysfunction or malignancy(50). Further sub-classified based on the presence of 
nodular elements is also possible. Goitre may also be associated with hyperfunction 
either due to diffuse hyperthyroidism such as associated with Graves' disease or 
functional autonomy such as occurs in long-standing multinodular goitre (toxic 
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multinodular goiter) that evolves through phases of diffuse enlargement, multinodular 
change and ultimately functional heterogeneity between nodular areas. (1, 21, 45, 46). 
NODULAR THYROID DISEASE 
General 
Nodular thyroid disease and goiter are the most frequently encountered manifestations of 
thyroid disease (41, 54). They exhibit a slight female predilection, although age, iodine 
nutrition and family history are the most important modifiers of risk (21, 54, 55). In 
particular, the prevalence of goitre is largely determined by the adequacy of iodine 
nutrition (24, 45, 46, 52, 56). For example, in iodine deficient Jutland, goiter was present 
in 12.2% of females and 3.2% of males, whereas in the genetically similar but iodine 
sufficient Icelandic population the prevalence was 1.9% and 2.2% respectively(48). In 
iodine deficient communities goiter prevalence also varies depending on the severity of 
the deficiency and the presence of other goitroegenic factors(24-26). 
Thyroid nodules are common in both iodine deficient and sufficient populations, the 
apparent prevalence of thyroid nodules greatly influenced by the mode of evaluation(41, 
50, 57). The prevalence of a palpable thyroid nodules was 1.6% and 6.4% for men and 
women respectively in the Framingham study(58). Similarly, the Whickham study 
reported palpable nodules in 0.8% and 5.3% of men and women respectively(59). Unlike 
clinically apparent thyroid nodules, subclinical nodular thyroid disease is common(41). 
Ultrasonography is particularly sensitive, identifying nodules in approximately one third 
of adults, the prevalence increasing with age. Of note, even relatively large thyroid 
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nodules may be inapparent on clinical examination, with only 48% of 
ultrasonographically evident thyroid nodules >2cm being palpable (41, 50, 57). 
Furthermore, autopsy studies show prevalence of thyroid nodules to be even higher, 
ranging between 30-60%(60, 61). 
Thyroid Imaging 
Over the past two decades ultrasonography has been used increasingly as the primary 
modality for thyroid evaluation(41, 62, 63). Thyroid ultrasonography has the capacity to 
detect thyroid lesions as small as 2mm in diameter and has five-fold greater yield for 
identifying thyroid nodules than does palpation(53, 54, 57, 64, 65). High resolution 
ultrasonography with a transducer operating at frequencies between 7-13 MHz is 
typically used, providing good visualization of suprasternal thyroid tissue whilst 
accurately determining if thyroid nodules are solid or cystic (53, 62, 66). Volumetric 
assessment of overall thyroid and nodule size can be undertaken with a measurement 
error of 10-16%(50, 67). Limitations include lack of penetration through bone and air, 
making ultrasound an unsuitable modality for study of retrosternal thyroid tissue, and 
limited in ability to differentiate benign from malignant disease(53). 
Thyroid nodules identified by ultrasonography can be described as hyperechoic (greater 
echogenicity than normal thyroid tissue), hypoechoic (lower echogenicity) and isoechoic 
(similar echogenicity)(50, 68). The majority of thyroid nodules are solid, the majority of 
which are hypoechoic, with a significant minority exhibiting some degree of cystic 
change(41, 53, 57). In many studies, nodule prevalence based on ultrasonography in 
approaches 50% of the adult population, with increasing age a key determinant of 
increased prevalence (41, 46, 50, 64, 69). 
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Sonographic features of nodules that indicate benignity include the presence of a simple 
cyst, an hyperechoic and homogeneous echotexture, limited intranodular vascular flow 
on Doppler, a regular margin, coarse calcifications, and a thin halo. (1, 50, 70). Although 
these criteria confer a low risk of malignancy, they cannot fully exclude malignancy (1, 
53, 70). Given the high prevalence of thyroid nodularity in the general population and the 
inability of ultrasonography to exclude malignancy great potential exists to generate 
additional investigations when imaging studies such as ultrasonography are applied 
widely in an otherwise asymptomatic population(41, 50, 54, 71). 
Other modalities such as computed tomographic (CT) scanning, magnetic resonance 
(MR) imaging and thyroid scintography may also identify thyroid nodules(41, 50, 71). 
Thyroid scintography using either Technetium 99 pertechnetate or radioiodine can 
classify nodules according to their functional status. Whilst thyroid malignancies are 
almost always hypofunctioning or isofunctional, the majority (>75%) of thyroid nodules 
exhibit this appearance, yet only a minority (8-25%) of such nodules harbour 
malignancy(46, 50). 
Like ultrasonography, MR and CT imaging provides structural information regarding 
thyroid size, nodule number and characteristics. In addition they are a useful modality 
for assessment of retrosternal thyroid tissue and have some advantage over ultrasound 
with regard to reduced inter-observer variation for volumetric assessment of goiter 
size(50). However, they are not superior to ultrasonography for characterizing malignant 
potential. Thyroid ultrasonography is not only simpler and more cost effective, but it is 
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generally a more sensitive tool for evaluation of structural thyroid disease(2, 41, 53, 67). 
The role positron emission tomography (PET) imaging in the evaluation of thyroid 
malignancy is limited by technique availability, cost and radiation exposure. However, 
PET has been demonstrated to be a sensitive and specific modality for identifying 
malignant thyroid lesions(50). 
INVESTIGATION OF THYROID NODULES 
Evaluation of the patient with nodular thyroid disease has changed over the past three 
decades, largely reflecting the increased use of both TSH and fine needle aspirate biopsy 
(FNAB) in the initial work-up of patients with nodular thyroid disease(50, 65, 72-74). 
Current recommendations suggest an initial measurement of TSH, which, if suppressed, 
should be followed by an evaluation of thyroid autonomy/hyperfunction using an 
assessment of peripheral thyroid hormones and thyroid scintigraphy(50, 73, 75, 76). 
In those individuals with a dominant or otherwise suspicious lesion and a normal TSH 
(which represents the majority of patients with incidentally discovered thyroid nodules), 
FNAB for cytological evaluation is generally recommended(50, 76, 77). This approach 
is aimed at excluding thyroid carcinoma and stratifying patients into low risk and high-
risk categories. Patients at low a priori clinical risk with normal FNAB results can avoid 
surgical biopsy/ thyroidectomy(50, 78). Those individuals with suspicious or overtly 
malignant aspirates are referred for surgical resection of the nodule(50, 75, 76). This 
may involve either unilateral lobectomy or total thyroidectomy depending on whether 
malignancy is identified(50, 76). A proportion of individuals have non-diagnostic 
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aspirates, which contain insufficient thyroid cellular elements, and repeat biopsy or 
surgical excision is usually recommended (74, 76, 79). 
FNAB is undertaken using a 21-25 gauge needle(1, 2, 74, 80, 81). Between three and 
five aspirates are taken from the nodule, with each specimen containing at least five or 
six groups of ten to fifteen cells(74, 82). Palpable nodules may be amenable to biopsy 
without ultrasonographic guidance, although impalpable and incidentally discovered 
nodules frequently undergo biopsy using ultrasound-guided techniques(81, 83, 84). 
Adequate aspirates are often reported as either benign, indeterminate/suspicious or 
malignant(72, 74, 79, 83). In general, studies report malignancy in 5%, suspicious 
cytology in 10%, benign features in 70% and unsatisfactory sampling in 15% of patients 
undergoing FNAB(50, 72, 74, 79, 81). Ultrasound-guidance for FNAB improves the 
success rate for adequate sampling, particularly in lesions with a cystic component(85, 
86). 
The diagnosis of TC can be made on FNAB with a high degree of sensitivity and 
specificity(72, 87). The false negative rate for a benign aspirate is considered to be 
approximately 1-5% (50, 76, 88). Similarly, false positive cytological diagnosis of 
malignancy is relatively low in the range of 5%(88, 89). However, difficulty can arise in 
relation to aspirates consistent with a follicular neoplasm. Resection is recommended as 
these may represent either a follicular adenoma or malignancy (50, 72, 76, 79, 90). 
>• 
Where the diagnosis of TC is uncertain preoperatively, and histological confirmation is 
required, tumour resection by unilateral lobectomy with intra-operative frozen section 
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histolopathology may be used (72, 76, 91). In such cases, patients with clearly benign 
lesions need not proceed to total thyroidectomy, whilst those with carcinoma can be 
definitively treated at the time of initial surgery. In other cases, particularly for PTC, 
where diagnosis of carcinoma is made by histopathology on the paraffin embedded 
specimen, completion thyroidectomy is usually undertaken within a few days or weeks of 
the initial unilateral resection(76, 92, 93). 
PAPILLARY THYROID CARCINOMA 
General 
Thyroid cancer is the most common endocrine malignancy, accounting for approximately 
1% of total malignant diagnoses recorded by cancer registries(94-96). Four broad 
categories of thyroid cancer account for the majority of diagnoses — papillary (PTC), 
follicular (FTC), medullary (MTC) and anaplastic (ATC) (1, 2, 97). Depending on study 
methodology and geographic region, 50-90% of all diagnoses are PTC, followed by FTC, 
with other histotypes accounting for less than 15% (98-104). With the exception of MTC 
which arises from the C-cell elements of the thyroid, PTC, FTC and many ATC arise 
from the epithelial elements which give rise to the thyroid follicle(1, 2, 97). TC annual 
incidence ranges from 3-7 per 100 000 in most countries, however a wide variation in 
incidence rate is reported, both between geographic areas as well as within the same 
locality over time(94-96). In particular, the annual incidence of thyroid cancer in many 
countries has increased by over 50% in recent decades(94-96). 
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Classification 
The current World Health Organisation (WHO) . classification of PTC recognises 15 
morphological subtypes, including tall cell, columnar and follicular variants(105). An 
important revision to the current scheme was undertaken in 1988 (97, 105-108). After 
this time, the classification mandated any thyroid carcinoma displaying papillary 
features, whether as a dominant morphology or in conjunction with other elements (such 
as follicular development), be classified PTC(97, 105). This has the potential to inflate 
the apparent occurrence of PTC verses FTC. Similarly, the incidence of FTC may have 
increased due to the contemporary classification of minimally invasive FTC, an entity 
that previously may have been assigned a diagnosis of follicular adenoma(108). 
Molecular Pathogenesis 
The genesis of PTC appears to be that theorized for other carcinomas in which successive 
mutations involving growth regulating genes lead to the ultimate development of a 
malignant phenotype(109-113). A progression through the sequential steps of 
hyperplasia, benign adenoma and ultimately, carcinoma has been postulated, although 
there is paucity of evidence to suggest benign thyroid neoplasms (follicular adenoma) 
undergo malignant transformation(46, 114). Whilst the thyroid gland is particularly 
prone to developing hyperplastic nodules, these per se do not appear to increase 
significantly the risk of PTC(21, 46). 
A number of genes are linked to the development of PTC, including RAS, Ret/PTC, TRK, 
BRAF, p53, MET and PAX8(49, 109, 110, 115-117). The initial molecular genetic 
alterations in PTC pathogenesis are poorly characterized, although activation of the MAP 
kinase pathway (which influences cell proliferation and survival) by BRAF mutations 
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appear important (109, 118). Of particular interest are ret/PTC mutations. Fusion of 
RET to the promoter region of an unrelated gene gives rise to these mutations collectively 
termed ret/PTC rearrangements(119). This chimeric oncogene results from activating 
mutations involving RET (a proto-oncogene encoding a receptor tyrosine kinase) that 
may arise after thyroidal irradiation(115, 120-125). The most prevalent of these are 
RET/PTC1 and RET/PTC3(119, 126, 127). Both mutations result from inversions 
involving the long arm of chromosome 10. High levels of radioiodine fallout following 
the Chernobyl accident produced an early and overt rise in childhood PTC associated 
with the RET/PTC3 rearrangement(115, 121). 
Subsequent studies have also shown RET/PTC1 to be associated with adult PTC 
developing after radiation exposure, particularly those associated with PTC developing 
after long latency (>10 years) following childhood exposure to radioiodine fallout(115, 
116, 119, 124, 128). Of note, studies following the Chernobyl accident indicate that 
whilst RET/PTC3 was three fold more common than RET/PTC1 in the first decade after 
irradiation, this ratio was reversed in PTC diagnosed after a long (>10 year) latency from 
radioiodine exposure (115, 124). The RET/PTC1 rearrangement has also been associated 
with tumour behaviour and prognosis, some studies suggesting an association with a 
relatively benign clinical pattern of disease(111, 117, 119, 129, 130). 
Ionising Radiation 
Only ionising radiation has a well established exposure-risk relationship for TC (131- 
135). The dominant malignancy arising after thyroid irradiation is PTC. Both ingestion 
of radioiodine and external beam exposure are linked to thyroid cancer(133-136). It is 
recognised that the latency between radiation exposure and the development of thyroid 
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cancer can span decades(133, 135). Whilst there exists no apparent threshold for 
induction of thyroid neoplasia, the risk is greatest when exposure to ionizing radiation 
occurs during early childhood, the resultant carcinoma potentially presenting in 
adulthood. In the case of the Chernobyl reactor disaster, the exposed population 
experienced a substantial rise in childhood PTC within a decade, but the increased 
incidence persisted for many years thereafter, indicating that PTC may occur at both 
short as well as long latency after thyroidal exposure to radioiodine. (132, 133, 135, 137, 
138). 
Consequential to the Chernobyl reactor accident, it has been proposed TC incidence 
increased in locations as distant as Connecticut in the United States of America(139- 
141). Closer to the site of the disaster, in Belarus, substantial incidence increases in 
thyroid cancer have occurred in recent years(132, 134, 142, 143). Genetic susceptibility 
and baseline iodine nutrition appear to modulate thyroid cancer risk after ionising 
irradiation. Low levels of dietary iodine elevate thyroidal uptake of radioiodine, 
increasing neoplasia risk(144-146). Human thyroidal exposure to nuclear fallout is likely 
to be mediated by consumption of factors such as cows milk, which bio-accumulates 
radioiodine (144, 147, 148). Low-level exposure by this mechanism has the potential to 
affect large populations. 
Whilst the magnitude of effect expected from low level radioiodine fallout is unclear, the 
possibility of some influence on population PTC epidemiology is supported both by data 
arising from the Chernobyl accident as well as the observations made following 
contamination of South Pacific islands by the Bikini Atoll weapons test (134, 139). By 
extrapolation, the linear dose response relationship, in conjunction with the absence of an 
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effect threshold and a protracted effect latency, suggests low level radioiodine fallout in 
conjunction with preexisting iodine deficiency may increase (albeit subtly) PTC 
incidence many up to years after the initial exposure (133, 134, 146). Conversely, studies 
to date in the populations affected by both the Nevada weapons tests and the Hanford 
event, have failed to show any convincing increase in thyroid malignancy(134). Further 
appropriately powered studies, with sufficient exposure data for participants, are needed 
to resolve this ambiguity(141, 149). 
Familial Susceptibility 
A number of familial syndromes are associated with an increased risk for follicular cell 
malignancy - familial polyposis coli, Cowden's syndrome and Peutz-Jaegers 
syndrome(96, 150). These syndromes result from genomically diverse mutations, 
providing further indication of multiple loci for genes involved in regulating thyrocyte 
growth. In addition, familial PTC with an autosomal dominant inheritance pattern is 
increasingly reported (96, 151-156). Loci for papillary carcinoma and familial non-
medullary thyroid carcinoma have been suggested for chromosome 1401 and 
chromosomes 3 and 8 (translocation) (157, 158). Present data suggest familial autosomal 
dominant PTC is likely to be a genetically heterogeneous disorder, with potential 
phenotypic overlap with benign nodular goiter(159). Identification of families at 
increased risk of PTC offers the potential to offer pre-symptomatic screening and 
improve prognosis (160). 
Iodine Nutrition 
The relationship between iodine nutrition and thyroid carcinoma pathogenesis is 
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complex. Epidemiological data show a trend for TC rates to be greater in populations 
with higher iodine intake (25, 27, 29, 131, 161-163). Of note, despite similar genetic 
backgrounds, Iceland (which has a high iodine intake) has a TC rate four-fold that of 
Denmark where iodine intake is lower(95, 164). It has been observed that FTC and 
anaplastic thyroid carcinoma occur relatively more frequently in iodine deficient 
populations, whereas PTC is more dominant in areas of iodine sufficiency(161, 165). 
However, this is not a universal finding as high rates of PTC can be found in both iodine 
deficient and iodine sufficient populations. Nonetheless, there is a tendency to higher 
PTC rates in those populations that have the highest levels of iodine nutrition. 
Improved iodine nutrition in previously iodine deficient communities has also been 
associated with increased PTC incidence(31, 163, 166). This effect, which has been 
called "papillarization", and is characterised by an increase in the PTC : FTC incidence 
ratio, a fall in PTC size and an attenuation of malignant phenotype(28, 31). Of note, the 
increase in PTC following iodine supplementation is largely attributable to a rise in small 
lesions - tumours that generally have a good prognosis(167, 168). The biological 
mechanisms underlying this observation is unclear, however subtle changes in TSH 
secretion induced by improved iodine nutrition are a possible link. However, the 
relative contribution of improved health standards (resulting in increased thyroid 
evaluation) versus a true change in disease pathogenesis remains to be clarified (29, 168- 
170). 
Incidental and Asymptomatic PTC ("occult" PTC) 
Incidental diagnoses of TC are frequently made at autopsy and routine histopathology of 
24 
thyroid tissue resected for benign indications (171). Mortison et al in 1954 showed that 
2.8% of thyroid glands from one thousand consecutive autopsies performed at the Mayo 
Clinic harbored TC (61). These tumours were not clinically evident antemortem. Careful 
histopathological evaluation of thyroid tissue resected for non-malignant indications can 
also result in the diagnosis of thyroid malignancy(172). Similarly, cytological evaluation 
of thyroid nodules incidentally detected during imaging of other neck structures may 
result in the detection of TC(173). Overall, prevalence estimates from surgical and 
autopsy series suggest an underlying rate of 5% in the adult population (41, 172, 174). 
The vast majority (>90%) of these tumours are PTC(60, 71, 172). 
Papillary Microcarcinoma 
Papillary microcarcinoma can be defined as a PTC of <l cm in maximum dimension(175- 
177). The prevalence of papillary microcarcinoma is largely determined by the sensitivity 
of the screening process used for their identification. In one autopsy study, systematic 
fine sectioning and staining of thyroid specimens revealed a prevalence of 22% compared 
to 4.6% when a less sensitive macroscopic evaluation was used(178). Many lesions are 
smaller than 5mm in diameter (179). 
Papillary microcarcinoma are frequently multicentric (93, 171, 174, 180). 
Approximately one third of patients with PTC can be shown to have more than one focus 
of carcinoma (93, 181). The likelihood of finding multicentric PTC is directly related to 
the acuity with which the thyroid tissue is examined, and does not appear related to 
clinical stage of the initial tumour (93, 181). Some will be coincidental "occult" PTC 
(given the high prevalence in a community of such lesions) but a proportion may 
represent a multicentric process originating from a common aetiological factor. 
25 
The origin of multifocal papillary thyroid carcinoma has been the subject of debate with 
two options proposed: either a multifocal process where tumours develop independently 
within the thyroid (possibly with an underlying predisposing factor), or tumours arising 
as metastases from one primary tumour (96, 111). The former appears to be the most 
common explanation, as studies have identified a range of different mutations suggestive 
of distinct clonality in tumours at different sites within the same thyroid gland (111). 
A body of both direct and indirect information suggests that the biological behavior of 
"occult" papillary microcarcinoma is less aggressive than clinically evident and larger 
PTC (117, 176, 177). However, these tumours are not invariably "benign" in their 
behaviour, with some patients developing metastatic disease and a 1% disease specific 
mortality (93, 175, 176, 180, 182, 183). These tumours may form a pool of precursor 
lesions of which a minority ultimately acquire mutations that allow progression to 
aggressive growth and metastases. Acquisition of growth dysregulating mutations by 
microcarcinoma may then result in progression to clinical disease(117). However, it 
appears many of these tumours remain asymptomatic, with a proportion undergoing 
spontaneous resolution. 
CLINICAL ASPECTS OF PTC MANAGEMENT 
Tumour Staging 
A number of staging systems are used in relation to PTC. These include TNM, MACIS, 
AMES, AGES and EORTC (76, 184-186). These systems represent different attempts at 
accurately predicting prognosis, and adequately identify the 70-85% of patients in whom 
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disease specific mortality is unlikely (76). The TNM system is typical and often used by 
tumour registries. It comprises three elements —size of primary tumour (T), the presence 
or absence of regional lymph node metastases (N), and the presence or absence of distant 
metastases (M) (76). The anatomical extent of thyroid carcinoma can be effectively 
characterised by the TNM system with the classification based on data originating from 
either clinical (cTNM) or pathological (pTNM) information. The four stage groupings 
for differentiated TC, further incorporate age >45 or <45 years into the classification 
scheme(184). 
Surgical Management 
Complete tumour excision is essential for the management of PTC (76). However, 
debate exists with regard to the role of total or near total thyroidectomy, as opposed to 
ipsilateral thyroid lobectomy, for low risk very small PTC (76, 96, 183, 185). Most 
authorities currently recommend total thyroidectomy for all PTC, although ipsilateral 
lobectomy and isthmusectomy is advocated in some circumstances for papillary 
microcarcinoma (76, 96). Completion thyroidectomy is usually undertaken in patients in 
whom a unilateral lobectomy for a non-malignant indication reveals PTC (76). An 
important benefit of total thyroidectomy relates to the frequent occurrence of multifocal 
PTC that involves not only the ipsilateral but also the contralateral lobe. Furthermore, 
total thyroidectomy is an important prelude to radioiodine ablation and subsequent 
thyroglobulin based follow-up protocols (76, 187). 
Damage to the recurrent laryngeal nerve and permanent hypoparathyroidism are the 
major complications of thyroidectomy (101, 188, 189). Both should occur in less than 
2% of patients (188, 189). Following total thyroidectomy, transient hypocalcaemia may 
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occur in as many as one quarter of patients (188). However, parathyroid function 
recovers in the majority of these individuals with time. 
Radioiodine Ablation 
Ablation of residual thyroid tissue and tumour is frequently recommended. 1 131 for 
differentiated thyroid carcinoma (PTC and FTC) has limited impact on surrounding 
tissue in comparison to deep x-ray therapy (76). However, debate surrounds the benefit 
of 1 131 treatment in improving prognosis for low risk tumours, particularly "occult" 
papillary microcarcinoma (76, 185). Nonetheless, radioiodine ablation has the benefit of 
eliminating residual normal thyroid tissue, making thyroglobulin a sensitive marker of 
tumour recurrence (76, 187). Patients receiving 1 131 require an appropriate degree of 
TSH stimulation of neoplastic and residualnormal thyroid tissue (76). This is achieved 
by either thyroid hormone withdrawal for up to six weeks or use of recombinant TSH 
prior t 
o administration of radioiodine. 
Surveillance 
Long term follow-up of patients with PTC is required (76, 92). Optimal management 
requires TSH suppression, monitoring of serum thyroglobulin and periodic 
ultrasonographic neck imaging (76, 92, 187). In some cases additional imaging using 
conventional imaging, radionucleide scintigraphy or positron emission tomography is 
required (76). The frequency of follow-up and the modality used is determined by the 
clinical situation and the prognostic category of the carcinoma (76, 187). 
Prognosis 
The prognosis of PTC is generally excellent (76, 185, 190). The vast majority (>90%) of 
patients diagnosed with PTC are effectively rendered disease free by thyroidectomy and 
radio-iodine ablation (76, 92, 185, 186, 191). Most patients have stage 1 disease for 
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which long term disease free survival exceeds 95% (183, 186). 	Papillary 
microcarcinoma (particularly "occult" disease) has an excellent prognosis with a cause 
specific mortality of <1% (175, 176, 183). Later stage, older age at diagnosis and male 
gender are associated with a higher risk of disease recurrence and PTC related mortality 
(186, 191). 
Disease related mortality is often a result of pulmonary metastases or local aero-digestive 
invasive disease. However, disease recurrence is frequently treated effectively by 
surgical resection and radioiodine (76). The risk of recurrence is greatest within the first 
decade following initial treatment and is also higher in the those individuals aged under 
20 years and over 60 years at the time of initial diagnosis(191). Mortality rates are 
lowest in patients aged under 40 years rising with increasing age over 40 years (191). The 
mortality rate for PTC at 25 years post treatment is approximately 5% whilst tumour 
recurrence is 14% (185, 191). 
GLOBAL INCIDENCE PATTERNS FOR PTC 
Geographic Distribution and Ethnic Susceptibility 
The absolute incidence of TC varies significantly between geographic locations. Some 
of the highest incidence rates are recorded in Iceland and the Philippines, whilst the 
United Kingdom and New Zealand report amongst the lowest (Table 1.1)(94, 95, 164). 
A significant correlation between ethnicity, independent of country of residence, is also 
seen (Table 1.2) (94, 95, 164). For example, ethnic Filipino residing in Hawaii have TC 
incidence rates which are more than two fold higher than those occurring amongst ethnic 
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Japanese and Chinese in the same community (94, 95, 164, 192). Interestingly, Hawaii 
has higher rates of thyroid carcinoma for each of these ethnic subgroups than is observed 
for the same ethnic groups living on the North American mainland (Table 1.2) (94, 95, 
164, 192). Given the relative comparability of health care between locations, these 
divergent results at different geographic sites suggest environmental as well as genetic 
factors play a role in the pathogenesis of TC. 
Temporal Trends 
Aside from differences between communities for absolute incidence, a significant 
temporal increase has occurred for the incidence of TC within many communities over 
recent decades. Substantial increases have occurred in both industrialised and developing 
nations, as well as in places as geographically diverse as Australia, the United States and 
Europe (Table 1.1, 1.2, 1.3) (94, 95, 164). This change is notably evident for PTC, 
whereas there has been little apparent alteration in the incidence of other carcinoma 
subtypes. Incidence rates for PTC have risen (in some cases by over 400%) during the 
past half-century (96, 98, 103, 131, 140, 193-199). The rise in TC incidence has occurred 
in a variety of jurisdictions with varying ethnic backgrounds (Table 1.1, 1.2) (94, 95, 
164). 
Longitudinal data collected by national registries is susceptible to biased case 
ascertainment (200, 201). Length bias, lead time bias and variation in the completeness 
of case registration all contribute (71, 201). Length bias is particularly relevant to PTC 
(71, 201). As the prevalence of clinically overt PTC is less than 0.1% and "occult" 
papillary microcarcinoma is detectable in 0.45-13% of adults from the general 
population, any increase in the utilisation of ultrasonography, particularly ultrasound 
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guided FNAB of non-palpable nodules, is likely to result in increased diagnosis of 
"occult" PTC (41, 71, 84, 141, 168, 179, 196, 202, 203). If the entire pool of occult PTC 
were identified antemortem, the resulting ascertainment bias could alone result in a 50- 
fold rise in the apparent incidence of PTC (16, 17, 18, 21, 61, 71, 174, 204, 205). 
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Table 1.1 	Global comparison of age standardised rates for thyroid cancer and 
the relative change in rates between 1983-1987 and 1993-1997. 
Country ASR (1983-87) ASR (1993-97) ASR Relative A 
Male Female Male Female Male Female 
Iceland 6.2 8.3 4.3 12.6 -30.7 51.8 
Manila 3.5 8.6 2.9 9.7 -17.1 12.8 
Belarus 0.6 1.9 2.3 8.5 283.3 347.4 
USA (white) 2.2 5.8 2.8 7.7 27.3 32.8 
Hong Kong 1.5 5.7 1.9 7.1 26.7 24.6 
Canada 1.7 4.3 2.1 6.4 23.5 48.8 
NSW &Vic 1.3 3.2 2.0 5.6 53.9 75.0 
Norway 1.6 5.1 1.5 4.3 -6.3 -15.7 
USA (black) 1.0 2.7 1.4 4.0 40.0 48.2 
Shanghai 0.9 2.2 1.1 3.8 22.2 72.7 
St Petersburg 1.1 2.9 1.3 3.8 18.2 31.0 
New Zealand 1.1 3.0 1.7 3.5 54.6 16.7 
Sweden 1.6 3.8 1.3 3.5 - 18.8 -8.6 
Denmark 1.0 2.0 1.0 2.3 0.0 15.0 
Ireland 1.0 2.2 0.9 1.9 -10.0 -13.6 
UK 0.7 1.5 0.8 1.9 14.3 26.7 
Data derived from "Cancer Incidence in Five Continents", Volumes VI and VIII, IARC Press, Lyon, France. 
Parkin DM, Whelan SL, Ferlay J et al (eds). Cancer incidence in five continents Vol VIII. IARC Sci 
Pub! 5, Lyon, 2002. 
Parkin DM, Muir CS, Whelan SL et al (eds). Cancer incidence in five continents Vol VI. IARC Sci 
Pub! 5, Lyon, 1992. 
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Table 1.2 	Ethnic comparison of age standardised rates for thyroid cancer and 
the relative change in rates between 1983-1987 and 1993-1997. 
Ethnic 
Background 
ASR (1983- '87) 
(Case/100000) 
ASR (1993-'97) 
(Case/100000) 
ASR Relative A (%) 
Male Female Male Female Male Female 
Scandinavian 
Iceland 6.2 8.3 4.3 12.6 -30.7 51.8 
Sweden 1.6 3.8 1.3 3.5 -18.8 -8.6 
Denmark 1.0 2.0 1.0 2.3 0.0 15.0 
Chinese 
Hong Kong 1.5 5.7 1.9 7.1 26.7 24.6 
Hawaii 8.1 11.3 4.6 6.7 -43.2 -40.7 
Los Angeles 2.0 3.1 1.7 6.1 -15.0 96.8 
Shanghai 0.9 2.2 1.1 3.8 22.2 72.7 
Filipino 
Hawaii 6.6 24.2 5.0 19.4 -24.2 -19.8 
Los Angeles 4.6 7.9 5.0 12.1 8.7 53.2 
Manila 3.5 8.6 2.9 9.7 -17.1 12.8 
Japanese 
Hiroshima 1.9 5.6 2.1 10.5 10.5 87.5 
Hawaii 4.3 6.3 1.9 7.3 -55.8 15.9 
Los Angeles 1.4 6.9 1.6 4.8 14.3 -27.5 
Anglo-Celtic 
Ireland 1.0 2.2 0.9 1.9 -10.0 -13.6 
UK 0.7 1.5 0.8 1.9 14.3 26.7 
Data derived from "Cancer Incidence in Five Continents", Volumes VI and VIII, IARC Press, Lyon, France. 
Parkin DM, Whelan SL, Ferlay J et al (eds). Cancer incidence in five continents Vol VIII. IARC Sci Publ 5, 
Lyon, 2002. 
Parkin DM, Muir CS, Whelan SL et al (eds). Cancer incidence in five continents Vol VI. IARC Sci Publ 5, 
Lyon, 1992. 
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Table 1.3 Australian comparison of age standardised rates for thyroid cancer and the 
relative change in rates between 1983-1987 and 1993-1997. 
Location ASR (1983- '87) 
(Case/100000) 
ASR (1993-'97) 
(Case/100000) 
ASR Relative A (%) 
Male Female Male Female Male Female 
NT na na 1.3 6.4 - - 
New South Wales 1.3 3.6 2.2 6.3 69.2 75.0 
Tasmania 1.0 3.4 1.9 6.0 90.0 76.5 
Queensland na na 1.9 5.8 - - 
Western Australia 1.4 3.7 1.5 5.0 7.1 35.1 
South Australia 1.0 3.4 1.8 5.0 80.0 47.1 
ACT 1.1 6.8 1.4 4.4 27.3 -35.3 
Victoria 1.3 2.7 1.6 4.3 23.1 59.3 
Data derived from "Cancer Incidence in Five Continents'', Volumes VI and VIII, IARC Press, Lyon, France. 
Parkin DM, Whelan SL, Ferlay J et al (eds). Cancer incidence in five continents Vol VIII. IARC Sci Pub! 5, 
Lyon, 2002. 
Parkin DM, Muir CS, Whelan SL et al (eds). Cancer incidence in five continents Vol VI. IARC Sci Pub! 5, 
Lyon, 1992. 
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CHAPTER 2 
Temporal trends for thyroid carcinoma in Australia: a rising 
incidence of papillary thyroid carcinoma (1982 — 1997). 
35 
Prologue 
The key questions addressed in this chapter are: 
1 	Has PTC incidence increased in Australia? 
2 	Are patterns of PTC incidence uniform across Australia? 
Presentations and publications arising from this Chapter: 
Presented 
Preliminary results presented at the International Congress of Endocrinology (ICE 
2000), Sydney, Australia, 2000. 
Published 
Burgess JR. 2004 Temporal trends for thyroid carcinoma in Australia: an 
increasing incidence of papillary thyroid carcinoma (1982-1997). Thyroid 12:141- 
9. 
In accordance with the criteria for submission of thesis by previously published research, 
Chapter 2 is based on the above cited publication. 
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Aim 
1 	To evaluate TC incidence trends in Australia, with particular reference to PTC 
incidence. 
2 	To determine if Tasmanian TC incidence trends are representative of Australian 
national incidence patterns. 
3 	To assess the possible role of ascertainment bias and changes in risk factor 
exposure on TC incidence trends. 
Hypothesis 
1 	Increasing TC in incidence in Australia is due to increased diagnosis of PTC. 
2 	The Tasmanian population is an appropriate model for evaluating factors 
underlying thyroid carcinoma incidence trends in Australia. 
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Introduction 
Thyroid carcinoma (TC) is the most commonly encountered endocrine malignancy(94, 
95). Papillary thyroid carcinoma (PTC) is the most prevalent of the TC subtypes (98, 
194, 199, 206). Longitudinal data from population based cancer registries shows the 
incidence of PTC to have risen up to five-fold in a number of countries over the past six 
decades (94, 96, 98, 194). The explanation for this remains unclear(203, 207-209). 
Potential causes include increased ascertainment of "occult" papillary microcarcinoma as 
well as changing exposure to risk factors such as ionising radiation and iodine 
nutrition(203, 208-210). 
In Australia, state based Cancer Registry data also indicate TC incidence has increased 
during past two decades(94, 95, 164). Whilst previously published national data have not 
specifically evaluated trends for PTC, an hospital based study from New South Wales by 
Fahey et al suggested there had been an increase in the underlying incidence of PTC 
(210). A detailed analysis of national TC incidence trends, with particular reference to 
PTC incidence, is now required to evaluate the changes in TC incidence observed 
elsewhere in Australia. 
This report examines PTC incidence trends throughout Australia during the period 1982 - 
1997. 
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Subjects and Methods 
Australia comprises six States [Queensland (QLD), New South Wales (NSW), Victoria, 
Tasmania, South Australia (SA) and Western Australia (WA)] and two relatively less 
populated Territories. QLD, NSW, Victoria and Tasmania are on Australia's eastern 
seaboard, whist SA and WA are located to the mid south and far-west respectively of the 
Australian continent. 
By statutory regulation cancer registries in each State and Territory collect data on all 
diagnoses of cancer (excluding non-melanoma skin cancer). All public and private 
pathology facilities participate in the cancer registry program. Nationwide data is 
subsequently collated by the Australian National Cancer Statistics Clearing House. As of 
January 2001 a full data set for the entire Australian population was available for the 
period 1982 - 1997. 
Following Institutional Ethics Committee approval, the Australian National Cancer 
Statistics Clearing House provided de-identified case data on all diagnoses of thyroid 
carcinoma occurring in Australia between 1982 and 1997. Cases were assigned to one of 
four histopathologic categories; PTC, FTC, MTC, and ATC. There were additional 
minority diagnoses ("other diagnoses"). "Other diagnoses" is an heterogenous grouping 
containing other tumours for which thyroid was registered as the primary site. The 
dominant components were Hurthle cell malignancy (26%) and "carcinoma not 
otherwise specified" (NOS) (18%). The remainder of this grouping comprised multiple 
diagnosis codes, some of which may represent incorrect classifications. It was not 
possible to further evaluate this from the data available. 
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Age standardised incidence rates (ASR) were estimated using the world standard 
population age and gender weights, and are expressed per 100 000 of population(211). 
Normally distributed variables were analysed using the Student's t-test. Time trends in 
incidence rates were analysed by linear regression of the rates on year at diagnosis. 
Where appropriate, numerical data is presented as Mean ± Standard Error of Mean 
(SEM). 
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Results 
During the period 1982 — 1997 there were 9053 new diagnoses of TC in Australia. The 
overall female to male ratio was 2.68 and the median year for TC diagnosis was 1992. Of 
the TC categories PTC, FTC, MTC, ATC and "other diagnoses" accounted for 65.8%, 
17.8%, 4.6%, 1.3% and 10.5% of cases respectively. 
The age standardised incidence rate for all TC combined increased from 2.889 per 100 
000/year to 5.522 per 100 000/year for females (p<0.001) and 1.272 per 100 000/year to 
2.039 per 100 000/year for males (p<0.001) (Table 2.1, 2.2, Figure 2.1) over the study 
period. TC incidence rates increased by 6.7% per year for females and 4.4% per year for 
males between 1982-1997 (p<0.001). The increase was primarily due to a 10.7% per 
year (p<0.001) and 8.3% per year (p<0.001) rise in PTC incidence for females and males 
respectively (Table 2.1, 2.2, Figure 2.1, 2.2). The incidence of remaining species of TC 
did not change appreciably between 1982-1997 (Table 2.1, Figure 2.2, 2.3). The median 
age at diagnosis with PTC increased during the study period from 38 and 42 years to 43 
and 46 years for females and males respectively (Table 2.1). The female to male 
incidence ratio did not change significantly over the study period (Table 2.1). 
The proportion of patients with the follicular variant of PTC (fv-PTC) did not increase 
disproportionately relative to other PTC subtypes during the period of study (Table 2.1, 
Figure 2.4). PTC was observed to increase in all Australian States, however, the rise was 
most marked in the four eastern Australian states (Tasmania, QLD, Victoria and NSW) 
(Table 2.2, Figure 2.5). The greatest increase in incidence (24.7% per year) was 
observed in Tasmania (P<0.001) (Table 2.2, Figure 2.5). 
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Survival at two-, five and ten- years following PTC and FTC diagnosis improved 
progressively during the study period (Table 2.1). Survival for PTC and FTC improved 
in parallel (Table 2.1). In particular, the fatal incidence ratio (the ASR for patients dying 
within two years of diagnosis expressed in relation to the total ASR) for PTC decreased 
between 1982 - 1991 but remained relatively constant thereafter. A similar trend was 
observed for the FTC fatal incidence ratio. 
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Discussion 
Whilst the incidence of PTC has increased in Australia during the past two decades, that 
of non-PTC thyroid malignancy did not change appreciably (Table 2.1, Figure 2.1, 2.2, 
2.3). The increase in PTC is evident for both males and females, although the underlying 
differential in PTC incidence between genders is preserved (Table 2.1, Figure 2.2, 2.3). 
The rise in PTC may relate to two factors - a true increase in PTC incidence as well as 
the aggregate effect of biases arising from changes in clinical and diagnostic practice. 
Ultrasonography, FNAB and detailed histopathologic examination of benign 
thyroidectomy specimens can contribute to over-diagnosis of "occult" PTC (60, 71, 201, 
202, 204). It has been demonstrated that 30-50% of the adult population have 
ultrasonographic evidence of one or more thyroid nodules, the majority of which are 
asymptomatic and non-palpable lesions of no more than 1 cm diameter(41, 57, 66). 
However, approximately 5% of such nodules represent "occult" papillary 
microcarcinoma. Although many of these lesions remain clinically irrelevant, once 
identified, most are subject to FNAB and surgical resection(60, 72, 75, 201). 
Whilst FNAB is a useful and minimally invasive method for estimating the risk of 
malignancy, 5-15% of all FNAB are reported as either cytologically malignant or high 
risk thereof(72, 212). It might therefore be expected that one case of PTC will be 
diagnosed for every 20 non-palpable and asymptomatic thyroid nodules identified by 
ultrasound and subsequently evaluated by FNAB. Given ultrasound guided FNAB of 
small (<1cm), non-palpable intrathyroidal nodules is becoming increasingly utilised, the 
potential for over-diagnosis of "occult" and clinically irrelevant PTC is great(41, 71). 
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Whether the initial identification of an "occult" PTC occurs serendipitously at the time of 
neck ultrasonography for a non-malignant indication, or during careful histopathologic 
examination of a thyroidectomy specimen, the majority of these neoplasms are not 
destined to produce clinically relevant disease or impact on life expectancy(41, 71, 201). 
Unfortunately, most cancer registries do not directly collect data on tumour size and 
clinical presentation. It is therefore not possible from the available data to determine the 
degree to which increased identification of small and "occult" PTC has influenced 
overall PTC incidence rates in recent decades. 
Australian national trends for thyroid ultrasonography and FNAB have not been 
characterized adequately. However, the study by Fahey et al reported a rise in the 
number of PTC treated at a Sydney hospital over recent decades(210). The rise appeared 
equally attributable to an increase in both diagnosis of "occult" PTC as well as clinically 
relevant PTC(210). Extrapolation of this data to the national level would suggest at least 
half of the rise observed in Australian PTC incidence could be explained by increased 
use of ultrasonography and sensitive histopathological techniques(210, 213). 
Indirect evidence against ascertainment bias as the sole cause for the rise in PTC 
incidence observed in Australia can be found in trends for PTC mortality. Despite a rise 
in the incidence of PTC versus FTC, parallel improvement in two-, five- and ten- year 
mortality rates have occurred. As "occult" PTC usually have a benign natural history, if 
PTC incidence had increased only due to greater recognition of "occult" PTC, a 
disproportionate improvement in survival for patients with PTC relative to FTC would 
be expected. 
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In particular, increased diagnosis of "occult" PTC should be manifest as a fall in the 
ratio of PTC fatal incidence : total PTC incidence. A decline in this ratio is evident 
between 1982-1991. However, during more recent years, particularly during the period 
of peak PTC incidence (1993-1997) the ratio remained stable. The initial decline 
between 1982-1991 could relate to either improved standards of patient care or 
ascertainment bias. However, given a similar trend is evident for the FTC fatal incidence 
ratio, improved management seems the likely explanation. Appreciation of the 
importance of total/ near-total thyroidectomy for PTC in the 1980's may account for this. 
It has also been suggested that changes in diagnostic criteria, with reclassification of 
follicular tumours to fv-PTC might account for an apparent rise in incidence of PTC(106, 
107). This is not borne out in the Australian data. Whilst fv-PTC incidence has 
increased, this rise only partly accounts for the observed overall increase in PTC rates 
(Table 2.1, Figure 2.4). 
Marked variation in PTC incidence is evident between the Australian states (Table 2.2, 
Figure 2.5). The eastern Australian states have experienced a highly significant increase 
in annual PTC incidence, almost triple that of SA and WA (Table 2.2, Figure 2.5). As 
standards of health care in Australia are equivalent across states, the magnitude of 
ascertainment bias for contemporaneously incident tumours should be similar throughout 
Australia. Comparison of incidence trends between geographic regions ought therefore 
be valid. 
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The greatest relative and absolute rise in PTC incidence occurred in Tasmania (Table 2.2, 
Figure 2.5) (26). Whilst Tasmania is the most iodine deplete state in the Australia, it 
appears that much of the Australian eastern seaboard is also to varying extents 
ecologically iodine deficient. It is therefore interesting to note the greatest rise in PTC 
incidence outside Tasmania has also occurred in the intrinsically iodine deficient eastern 
states (Figure 2.5). 
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Conclusion 
The incidence of PTC has increased throughout Australia during the past two decades. A 
differential increase in PTC favouring higher rates in geographic regions at greatest risk 
of iodine deficiency is evident. Greater identification of prevalent, yet clinically "occult" 
PTC may account for part of the observed increase, however a failure to observe an 
ongoing improvement in patient survival despite rising PTC incidence suggests an 
increase in incidence of clinically significant disease has also occurred. This may be 
linked directly or indirectly to population iodine nutrition or prior exposure to risk factors 
such as ionising radiation. 
Further studies are required to 1) to confirm the accuracy of cancer registry case 
ascertainment, 2) to assess temporal trends for factors antecedent to the diagnosis of 
"occult" PTC, and 3) to seek evidence of geographic or temporal variation in PTC risk 
factor prevalence. Evaluation of these issues might be undertaken using the Tasmanian 
population as a model, given its stable demographic structure, and representative trends 
for PTC incidence. 
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Table 2.1 	Characteristics of thyroid carcinoma diagnosed in Australia 1982- 
1997 
Year of Diagnosis 
PTC FTC MTC ATC Other 
PTC(a11) [v-FTC 
1982-'85 
Number of cases 906 288 338 65 24 256 
Female (F):Male (M) ratio 2.76 3.30 2.76 1.50 3.00 1.91 
F/M Median age (y) 38 / 42 42 / 48 47 / 54 58 / 44 69 / 63 64 / 61 
F/M Incidence (ASR) 1.89 / 0.70 0.64 /0.20 0.69 / 0.27 0.10 / 0.07 0.04 / 0.02 0.42 / 0.26 
F/M 2-year survival (%) 92.0 / 88.4 93.2 / 92.5 89.1 / 83.3 84.6 / 76.9 0.0 / 0.0 51.8 / 48.9 
1986-'89 
Number of cases 1111 236 370 104 29 192 
Female (F):Male (M) ratio 2.75 2.69 2.90 1.54 1.64 2.55 
F/M Median age (y) 39 / 47 41 / 49 46 / 51 49 / 56 65 / 66 64 / 64 
F/M Incidence (ASR) 2.17 / 0.80 0.46 / 0.17 0.71 /0.25 0.15 / 0.11 0.04 / 0.03 0.29 / 0.14 
F/M 2-year survival (%) 96.1 / 88.2 97.0 / 87.5 94.9 /91.6 87.3 / 85.4 16.7 /9.1 53.6 / 57.4 
1990-'93 
Number of cases 1594 306 415 123 29 244 
Female (F):Male (M) ratio 3.29 4.19 2.58 1.05 2.22 1.68 
F/M Median age (y) 42 / 47 41 / 47 49 / 59 55 / 54 77 / 63 61 / 67 
F/M Incidence (ASR) 3.23 / 0.91 0.61 / 0.14 0.72 / 0.28 0.15 / 0.14 0.03 /0.02 0.32 / 0.21 
F/M 2-year survival (%) 96.6 / 88.4 97.2 / 90.0 95.0 / 90.5 87.3 / 80.0 30.0 / 0.0 70.5 / 59.3 
1994-'97 
Number of cases 2354 539 489 120 39 251 
Female (F):Male (M) ratio 3.00 3.46 2.76 1.03 1.29 2.64 
F/M Median age (y) 43 / 46 41 / 46 47 / 52 49 / 56 74 / 68 62 / 65 
F/M Incidence (ASR) 4.09 / 1.35 0.97 / 0.28 0.82 / 0.29 0.14 / 0.14 0.03 / 0.03 0.36 / 0.15 
F/M 2-year survival (%) 97.5 / 91.2 98.8 / 95.9 94.0 / 91.5 88.5 / 17.0 9.1 / 11.8 68.7 / 53.6 
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Table 2.2 Statistical characteristics of total thyroid carcinoma and PTC diagnosed in 
Australia 1982-1997 
Subgroup Average annual 
Increase 
(0/) 
Confidence Interval 
R2 P = 
Lower 95% Upper 95% 
Australian total TC 
Female 6.7 5.0 8.3 0.85 <0.001 
Male 4.4 2.9 5.8 0.75 <0.001 
Australian PTC 
Female 10.7 8.6 12.8 0.82 <0.001 
Male 8.3 6.1 10.5 0.82 <0.001 
PTC by State (M+F) 
Tasmania 24.7 17.8 31.6 0.81 <0.001 
QLD 14.1 10.2 18.0 0.81 <0.001 
Victoria 13.2 10.5 15.9 0.89 <0.001 
NSW 10.1 8.0 12.2 0.89 <0.001 
WA 5.8 2.7 8.9 0.54 =0.001 
SA 4.0 1.4 6.5 0.44 =0.005 
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Figure 2.1 Thyroid carcinoma incidence in Australia (1982 - 1997) 
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Figure 2.3 Thyroid carcinoma subtype incidence in Australia - males (1982 - 1997) 
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CHAPTER 3 
A review of thyroid carcinoma cases registered by the 
Tasmanian Cancer Registry (1978-1998) with particular 
reference to the accuracy of case classification 
and registration. 
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Prologue 
The key questions addressed by this chapter are: 
1 	Do changes in PTC classification or registration account for observed PTC 
incidence trends? 
2 	What contribution do small (<1cm) tumours make to PTC incidence trends? 
3 	Could historical variation in risk factors such as iodine nutrition explain observed 
PTC incidence trends? 
Presentations and publications in relation to this Chapter: 
Presented 
This work was presented in part at the 42nd meeting of The Endocrine Society of 
Australia, Melbourne, Australia, 1999. 
Published 
Burgess JR, Dwyer T, McArdle K, Tucker P 2000 The changing incidence and spectrum 
of thyroid carcinoma in Tasmania (1978-1988) during a transition from iodine 
sufficiency to iodine deficiency. J Clin Endocrinol Metab 85: 1513-1517. 
In accordance with the criteria for submission of thesis by previously published research, 
Chapter 3 is based on the above cited publication. 
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Aim 
1 	To assess the impact of changing histological diagnostic criteria on thyroid 
carcinoma incidence patterns. 
2 	To determine the relationship between PTC size and overall PTC incidence trends 
3 	To determine if evidence exists for a relationship between historical changes in 
iodine nutrition and PTC incidence trends. 
Hypothesis 
1 	Changes in Cancer Registry case ascertainment and histopathological 
classification are unlikely to fully explain observed incidence trends for TC. 
2 	Increased diagnosis of small PTC accounts for the majority of the observed 
increase in PTC incidence. 
3 	Incidence trends for PTC are influenced by iodine nutrition. 
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Introduction 
The previous chapter identified an increasing PTC incidence in Australia over the past 
two decades. Furthermore, a state-based geographic gradient for PTC incidence was 
identified in which the highest rate of increase was found in Tasmania. Tasmania is an 
island state of the Commonwealth of Australia and an area of endemic iodine 
deficiency(214, 215). 
A number of distinct phases of iodine prophylaxis can be identified in Tasmania. 
Initially, potassium iodide tablets were provided to Tasmanian school age children 
between 1950 and 1965, whereas in 1966 iodine supplementation via the addition of 
potassium iodate to bread commenced(214, 215). Contemporaneous with this, iodine 
contamination of milk supplies by iodine residues (from a newly introduced dairy 
disinfectant) also provided an additional source of dietary iodine. Consequently, a well-
documented transient increase in the incidence of iodine induced thyrotoxicosis occurred 
during the late 1960's and early 1970's(216). 
In 1974, iodine supplementation of bread was discontinued and, thereafter, milk provided 
the primary method of community iodine repletion(214). For commercial reasons, the use 
of iodine containing dairy disinfectants declined in the late 1980s. During the period 
1969-1981 only 4% of school children surveyed had urinary iodine to creatinine ratios 
less than 75 [ig/g, whereas, during the years 1982-1985 the percentage below 75 1.1g/g 
increased to 26%(214). Persistence of mild-moderate iodine deficiency has been 
confirmed by subsequent public health studies, including a 1996 analysis in which a 
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median urinary iodine excretion of 42 1.1g/L and in 2000 when median UIC was 
84iig/L(217). More recently, studies have indicated the emergence of iodine deficiency 
in the other Australian states(19, 218, 219). 
In this chapter, the incidence a:nd spectrum of TC in Tasmania during the years 1978— 
1998 is evaluated with particular reference to the accuracy of Cancer Registry 
documentation and TC initial histopathological diagnosis. This period spans the 
transition of the Tasmanian population from iodine sufficiency to iodine deficiency. 
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Subjects and Methods 
Data provided by the Australian Bureau of Statistics show that during the period 1978— 
1998 Tasmania's population increased by only 15% (62,000 persons) from a 1978 
population of 413,538 persons. The male to female ratio remained stable during this 
period, ranging between 0.98 and 1.00. Inpatient medical services were provided by one 
tertiary referral hospital and eight smaller hospitals distributed throughout the island. By 
statutory regulation the Tasmanian Cancer Registry received notification of all cases of 
cancer (excluding non-melanoma skin cancer) diagnosed in the Tasmanian population. 
Following approval by the Data Release Committee of the Tasmanian Cancer Registry, 
all cases of TC diagnosed during the period 1978-1998 were identified. A total of 298 
cases of TC were registered in Tasmania between 1978 and 1998. Histopathological 
evaluation of tissue specimens has been undertaken by four pathology services. Review 
of the original histopathology reports and/or allied clinical details resulted in exclusion of 
nine (3%) cases that did not satisfy diagnostic criteria for a primary TC. The remaining 
289 cases of primary TC were assigned to one of four diagnostic categories: PTC, FTC, 
MTC, and Other TC. To determine the comparability of diagnoses recorded by archival 
reports with contemporary diagnostic standards, original histology slides for all cases (n 
= 134) of PTC and FTC diagnosed during even numbered years commencing 1978 were 
sought for review by two histopathologists blinded to the original diagnosis. 
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Age standardized incidence rates were estimated using the world standard population age 
and gender weights(211). All incidence rates are per 100,000 of population. Data were 
analyzed using the Student's t test for normally distributed variables and the X2 test for 
nonparametric data. Where appropriate, numerical data is presented as mean ± SEM. 
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Results 
A total of 289 incident cases of TC were identified in Tasmania during the 21-year period 
spanning 1978-1998. PTC, FTC, MTC, and other TC accounted for 180 (62%), 67 
(23%), 12 (4%), and 30 (11%) cases, respectively (Table 3.1). Of the 30 cases of other 
TC, 21(70%) were classified as either anaplastic or undifferentiated thyroid cancer. The 
mean age at diagnosis was 50.8 ± 1.0 year, and the male to female ratio was 1:2.8 (Table 
3.1). The median year for diagnosis was 1992. The age standardized incidence of TC 
(male and female) increased by 2.3-fold (from 0.75 to 1.76 per 100,000) and 2.2-fold 
(from 2.45 to 5.33 per 100,000), respectively, between 1978-1984 and 1992-1998 
(Figure 3.1)(P < 0.05). 
The overall increase in incidence for TC resulted predominantly from a rise in the 
incidence for PTC by 4.5- and 2.1-fold in females (P < 0.05) and males (not significant), 
respectively, between the periods 1978-1984 and 1992-1998 (Figure 3.2). The incidence 
of other categories of thyroid cancer did not change significantly (Table 3.1). During this 
time, the overall FTC/PTC ratio decreased from 0.74 to 0.24 (P < 0.005). The rise in 
incidence of PTC was observed in all Tasmanian population regions, spanning all 
pathology services. The rise in PTC incidence was, mostly, due to an increase in tumors 
of <1 cm in diameter; however, a 3-fold rise in incidence of larger lesions also occurred 
during the study period (Table 3.2). 
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Diagnoses of PTC were made at autopsy in eight (4%) cases. For non-PTC carcinoma, 
the presence of multinodular histopathology as a co-pathology in thyroid specimens 
remained stable during the study period (20% vs. 21%) between 1978-1984 and 1992— 
1998, respectively. During this time, the prevalence of multinodular change occurring in 
association with PTC increased from 11% to 36% (P < 0.05). Nine (5%) patients with 
PTC had an immediate familial history of PTC in which at least one first-degree relative 
was affected. This included two pairs of monozygotic twins with concordant 
development of PTC. Multifocal and metastatic PTC were identified in 43 (24%) and 33 
(18%) patients, respectively (Table 3.2). Seventeen (40%) patients with multifocal PTC 
had bilateral tumours. 
Histopathological material from 108 patients (diagnosed in the even numbered years) 
was available for prospective re-examination by two histopathologists blinded to original 
diagnoses. This sample represented 47% of all PTC and 34% of all FTC diagnosed 
during the entire time period from 1978-'98. Diagnostic reclassification occurred for five 
(6%) PTC and four (17%) FTC (Table 3.3). Of the reclassified PTC's, three were 
considered to be FTC and two were classified as papillary oncocytic neoplasms. Of the 
reclassified FTC, two were considered to be PTC and one each an adenoma and 
anaplastic carcinoma. Reclassifications did not alter the temporal trends observed at the a 
priori examination of original pathology reports. 
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Discussion 
Consistent with the findings of Chapter 2, there was a significant rise in the incidence of 
TC during the study period. This resulted from an increase in incidence of small FTC. 
Changes in clinical practice, such as fine sectioning of thyroidectomy specimens resected 
for benign indications (such as multinodular goitre, increased use of ultrasonography and 
FNAB) may account for this. However, such factors are unlikely to fully explain the 
observed trends. By way of example, despite a rise during recent years of multinodular 
goiter occurring in association with FTC, the majority of patients with combined PTC 
and multinodular goiter had evidence of clinically relevant malignancy. Of the 39 cases 
of FTC associated with multinodular goiter diagnosed during the 1992-1998 period, in 8 
(21%) cases the FTC was more than 3 cm in diameter, in 11 (33%) cases it was 
multifocal, and in 2 (6%) cases it was metastatic. Furthermore, even when lesions of 1 
cm or less in diameter are excluded, a 3-fold rise in the incidence of larger FTC was 
evident (Table 3.2). 
The role of iodine nutrition in the pathogenesis of TC is both complex and 
controversial(29, 103, 161, 162, 220). Comparison of incidence rates between iodine-
deficient and iodine-sufficient communities yields conflicting results(95, 162). 
Similarly, case control studies have also produced contradictory findings, iodine-rich 
diets having been associated with both a heightened and an attenuated risk of TC(221- 
223). Despite this, a relatively consistent association has been the link between iodine 
nutrition and tumor histology(27, 161, 162). The incidence of FTC and anaplastic TC is 
greatest in iodine-deficient populations, whereas the converse is true in regions of iodine 
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sufficiency(29, 161, 163, 220). Consistent with this observation, iodine supplementation 
in previously deficient populations is associated with a rise in the proportion of PTC; so 
called "papillarization" of TC(28, 29, 161, 163, 220). This is evidenced by a rise in the 
proportion PTC relative to FTC(163, 166). 
Few studies of iodine nutrition had been undertaken on the Australian mainland prior to 
the recent National Iodine Nutrition Study (NINS) (218). Before the 1970's several 
localised areas with endemic goitre were recognised on the Australian east coast(17, 19, 
214, 224). Agricultural studies of ovine iodine nutrition and thyroid function indicate 
iodine deficiency in grazing sheep in Tasmania, Victoria, NSW and southern QLD(17, 
225). Similarly, the river systems of Australia's east coast have been shown to be iodine 
deplete(17, 224). The recent NINS confirmed a similar distribution of iodine deficiency 
in the contemporary human population of Australia(218). 
It is likely that iodine nutrition across much of Australia was rendered adequate 
unwittingly from the mid 1960's until the late 1980's by use of iodine based disinfectants 
(iodophors) in the Australian dairy industry, the residue of which enhanced milk iodine 
content(214). However, declining use of iodophor disinfectants over the past two decades 
appears to have unmasked underlying Australian regional variations in the ecological 
distribution of iodine deficiency(19, 218, 219). 
It is therefore notable that in Tasmania, the increase in PTC incidence described in this 
chapter has occurred despite the recurrence of iodine deficiency. A complex interaction 
between iodine nutrition and thyroid tumorigenesis may account for this. A study by 
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Galanti et al. indicated a possible differential effect for iodine prophylaxis on the 
spectrum of TC depending on an individual's age at the time of iodine exposure (27). 
The increasing incidence and predominance of PTC despite the fall in contemporary 
iodine nutrition could also reflect either a threshold for changes in iodine nutrition or a 
latency between changes in iodine intake and the clinical expression of neoplastic 
disease. 
It is also possible the current rise in PTC incidence relates to a delayed impact of the 
relative iodine excess occurring during the late 1960s and early 1970s (214, 215). 
Whereas this was associated with an acute increase in the incidence of thyrotoxicosis at 
the time, it may also have primed susceptible individuals, then in their childhood, for 
subsequent development of PTC as adults (214, 216). If this speculation is correct, a fall 
in the incidence of FTC might be expected over the following decade. 
Ionising radiation is the external aetiologic factor most clearly associated with an 
heightened risk of clinically significant TC(136, 137, 206). Nuclear fallout (radioiodine) 
and medical sources of ionising radiation confer an increased risk of both benign and 
malignant nodular thyroid disease(134, 136, 137, 139, 144). Exposure to ionising 
radiation during childhood increases the likelihood of FTC developing in adult life(133, 
137, 138, 209). Tumours occurring in this context are often multicentric and may 
develop after a latency of several decades(133, 136, 137, 226). Moreover, PTC rates may 
not reach a maximum until 30 years following the exposure(133, 136, 137, 226). 
Exposure to radioiodine fallout from nuclear weapon testing is a possible link between 
the distribution of ID in Australia and geographic patterns of FTC incidence(134, 226). 
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Atmospheric nuclear weapon testing occurred both in Australia and elsewhere in the 
South Pacific between 1950 and 1962 (227). The highest predicted susceptibility to PTC 
from fallout related to this maps to birth years 1945-1962. Children born during this 
period were exposed potentially to fallout at a time when community iodine nutrition was 
suboptimal, enhancing the risk of thyroidal exposure to ionizing radiation(134,214). 
Medical use of ionizing radiation in childhood is also associated with an heightened risk 
for PTC in adulthood(135). External beam radiotherapy was employed in the mid-
twentieth century for treatment of a diverse range of non-neoplastic conditions (135). 
The prevalence of such therapy in Australia is unclear and warrants further consideration 
as an etiological risk factor in the context of current PTC incidence trends. 
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Conclusions 
The increased incidence of PTC observed by Cancer Registries throughout Australia in 
Chapter 2 has been confirmed by detailed review of source documentation for cases 
registered by the Tasmanian Cancer Registry. An increase in small (<1cm) PTC is the 
major component of the observed change, although a minor increase in the incidence of 
large and aggressive PTC has also occurred. Potential explanations for this include both 
changes in clinical and diagnostic practice as well a rise in underlying thyroid 
tumorigenesis driven by factors associated with changes in iodine nutrition or exposure 
to ionising radiation. A more detailed review of clinical practice trends and risk factor 
exposure is required to further assess these possibilities. 
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Table 3.1 	Characteristics of thyroid carcinoma diagnosed during the calendar 
years 1978-1998 
Year of Diagnosis Papillary Follicular Medullary Other 
1978 — 1984 
n (% total TC) 27 (47) 20 (35) 2 (4) 8 (14) 
Crude Rate 0.90 0.67 0.06 0.26 
Age 46.8±2.9 57.8±3.6 42.5±21.0 71.8±3.9 
M:F 1 : 2 1 	: 5.7 0 : 2 1: 	1.7 
1985- 1991 
n (% total TC) 43 (54) 21 (26) 3 (4) 13 (16) 
Crude Rate 1.36 0.66 0.09 0.41 
Age 47.6±2.5 49.4±3.6 50.4±8.8 65.6±4.9 
M:F 1: 3.3 1: 3.2 1: 2 1: 	1.6 
1992 - 1998 
n (% total TC) 110 (72) 26 (17) 7 (5) 9 (6) 
Crude Rate 3.32 0.78 0.06 0.27 
Age 45.9±1.3 54.7±2.3 57.2±5.8 70.9±5.7 
M:F 1: 4.2 1: 1.4 1: 0.8 1: 0.8 
M:F — Male : Female ratio 
Crude rate — Crude incidence rate per 100 000 of population 
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Table 3.2 Changes in the spectrum of papillary thyroid carcinoma diagnosed 
during the periods 1978-1984, 1985-1991 and 1992-1998 
Characteristic 
1978 - 1984** 1985 - 1991 1992 - 1998** 
n (%) M:F n (%) M:F n (%) M:F 
27 1: 2 43 1:3.3 110 1:4.2 
Total cases 
Size <1.1 7 (26) 1: 2.5 12 (28) 1: 5.0 49 (45) 1: 5.1 
Size 1.1-2.0 8 (30) 1: 1.7 15 (35) 1: 4.0 33 (30) 1 : 4.5 
Size 2.1-3.0 5 (19) 1: 	1.5 9 (21) 1: 3.5 13 (12) 1: 5.5 
Size >3.0 5 (19) 1: 	1.5 7 (16) 1: 	1.3 13 (12) 1: 2.3 
Multinodular pathology 3 (11) 1: 0.5 12 (28) 1: 5.0 39* (36) 1: 3.9 
Incidental finding 3 (11) 1: 2.0 9 (21) 1: 8.0 33 (30) 1: 6.0 
Multifocal primary 1 (4) 0: 1.0 11 (26) 1 : 4.5 31 (28) 1 : 2.9 
Regional invasion 3 (11) 1 : 2.0 7 (16) 0 :7.0 12 (11) 0: 12 
Metastases 7 (26) 1 : 0.4 10 (23) 1 : 9.0 16 (15) 1: 	1.3 
Deceased 6 (22) 1: 	1 8 (19) 1: 1.7 6 (6) 1: 	1 
M:F - Male : Female ratio 
Size - Tumour size 
Multinodular pathology - Histopathological evidence of multinodular change in thyroid tissue. 
**Size unknown in 2 cases of papillary carcinoma. 
*Of these 39 cases of thyroid carcinoma, 8 were >3cm in diameter, 11 were multifocal, 2 were metastatic, 
and 16 were incidental findings. 
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Table 3.3 Comparison of original and contemporary histolopathological diagnoses 
for 108 cases of differentiated thyroid carcinoma. 
1978 - 1984 1985 - 1991 1992 - 1998 
n= % n= % n= % 
Orignial diagnosis- PTC 18 20 62 
Cases available for review* 15 83 16 80 54 87 
- PTC confirmed** 13 87 15 94 52 96 
Orignial diagnosis- FTC 10 10 14 
Cases available for review* 6 60 5 50 12 86 
- FTC confirmed** 4 67 5 100 10 83 
Original diagnosis - Diagnosis as recorded on the original histopathology report. 
*Histopathology slides were located and reviewed by pathologist. Percentage represents the proportion of 
patients for whom slides were located. 
**Re-examination of histopathology produced a diagnosis concordant with original diagnosis. Percentage 
represents the proportion of patients for whom the review diagnosis was concordant with the orignial 
diagnosis. 
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CHAPTER 4 
Incidence trends for PTC and their correlation with trends for 
thyroid surgery and thyroid FNAB cytology 
75 
Prologue 
The key questions addressed in this Chapter are: 
What is the completeness of Tasmanian Cancer Registry case ascertainment for 
diagnoses of PTC? 
2 	Has there been a change in patterns for utilization of FNAB and thyroid surgery? 
3 	Is there a relationship between thyroid imaging, FNAB and PTC incidence 
trends? 
Presentations and publications arising from this Chapter: 
Presented 
Preliminary results resented at the Endocrine Society of Australia, 2002 ASM, Adelaide, 
Australia. 
Published 
Burgess JR, Tucker P. 2006 Incidence trends for papillary thyroid carcinoma and their 
correlation with thyroid surgery and thyroid fine needle aspirate cytology. Thyroid 2006; 
16: 47-53. 
In accordance with the criteria for submission of thesis by previously published research, 
Chapter 4 is based on the above cited publication. 
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Aim 
1 	To confirm the adequacy PTC case ascertainment by the Tasmanian Cancer 
Registry. 
2 	To determine the relationship between thyroid surgical and cytological procedures 
and temporal trends for PTC diagnosis. 
Hypothesis 
Incidence trends for PTC are influenced by changing paradigms for evaluation and 
management of nodular thyroid disease. 
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Introduction 
Previous chapters demonstrated an increase in incidence of PTC in Australia generally, 
and Tasmania in particular(213, 228). Detailed review of source documentation and 
tissue samples for cases registered by the Tasmanian Cancer Registry confirmed both the 
accuracy of case registration as well as the consistency of histopathological classification 
over time. However, the potential for changes in TC case notifications over time could 
not be assessed by the methodology utilized in previous chapters. Progressive and 
systematic improvements in Cancer Registry case ascertainment is potentially an 
important source of bias. 
Prior chapters have also linked the ecological distribution of iodine deficiency in 
Australia with PTC incidence trends(17, 218, 228). As iodine deficiency is often 
associated with goitre monitoring programs, it is possible increased screening accounts 
for the majority of observed changes in PTC incidence(71, 200, 229, 230). In support of 
this I have previously identified an increase in the incidence of tumours <1.0cm, lesions 
which most likely represent asymptomatic and non-palpable PTC (occult PTC) (71, 170, 
228, 230). Such PTC generally have a "biologically benign" natural history (41, 71, 202, 
205). It is therefore possible that identification of non-palpable nodules by 
ultrasonography, and their subsequent cytological evaluation by FNAB, has merely 
increased the diagnosis of small and mostly clinically inconsequential tumours (41, 202, 
212, 230). At present however, there is a paucity of data directly relating trends for PTC 
incidence to trends in the use of neck ultrasonography, thyroid FNAB cytology and 
thyroid surgery (230). Such information would assist in determining the role, if any 
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contemporary medical practice has had on PTC incidence trends. 
Using the Tasmanian population as a model, this study sought to determine the 
relationship between changes in PTC incidence and trends for utilization of neck 
ultrasonography, thyroid surgery and thyroid FNAB cytology over an 11-year period 
during which PTC incidence increased more than two fold(213). 
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Subjects and Methods 
Hospital and pathology services in Tasmania submitted data relating to thyroid surgical, 
histopathological and cytological procedures undertaken between January 1988 and 
December 1998. This period was selected given the availability of comprehensive data 
relating to surgical procedures and pathology outcomes, in conjunction with the 
availability of accurate baseline cancer registry data for thyroid carcinoma (213). 
Furthermore, during this period Tasmania's population increased by less than 15% (213). 
In subsequent years population flux increased and data availability diminished. 
Data was cross-referenced against diagnoses of thyroid carcinoma independently 
assembled by the Tasmanian Cancer Registry - a statutory authority that receives 
notification of all cases of cancer (excluding non-melanoma skin cancer) diagnosed in 
the Tasmanian population (213). All tumours designated as primary thyroid carcinoma 
were assigned to one of four diagnostic categories; PTC, FTC, MTC, and "Other 
diagnoses" (213, 228). The category of "Other diagnoses" comprised anaplastic thyroid 
carcinoma, Hurthle cell malignancy and "carcinoma not otherwise specified". Cytology 
results from FNAB thyroid were classified into four categories; unsatisfactory sample 
(U), benign lesion (B), indeterminate lesion (I) and malignant (M). The indeterminate 
category comprised follicular lesions, oncocytic lesions, and other indeterminate or 
suspicious cytological appearances. 
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In addition, patients identified by the Tasmanian Cancer Registry with a diagnosis of 
PTC during the period 1978-1998 (n=180, Female:Ma1e=3.5, Age at diagnosis 46.4±1.1 
yeas) were also sought to determine the preoperative likelihood of TC. Of these, 99 
patients (Female:Male=4.8, Age at diagnosis 44.5±1.0 years) were living, contactable 
and consented to provide information regarding the original indication for thyroid 
surgery. 
Normally distributed variables were analysed using the Student's t-test. Time trends in 
incidence were analysed by linear regression of the rates on year at diagnosis. Numerical 
data is presented as Mean ± Standard Error of Mean (SEM). Age standardised incidence 
rates (ASR) were estimated using the World Standard Population age and gender 
weights, and are expressed per 100 000 of population (211). The study was approved by 
the Royal Hobart Hospital Research Ethics Committee and the Data Release Committee 
of the Tasmanian Cancer Registry. 
81 
Results 
In the years 1988-1998 a total of 3452 individuals underwent a thyroid procedure, 
comprising 1968 surgical procedures in 1920 patients (F:M 4.5:1) and 1756 FNAB 
cytological procedures in 1532 patients (F:M 5.3:1). A new diagnosis of TC was made in 
184 patients with a female to male ratio of 3:1. Of these, 175 patients had an 
histologically confirmed diagnosis - 121 (65.8%) PTC, 40 (21.7%) FTC, 7 (3.8%) MTC 
and 17 (9.2%) "Other diagnoses. When PTC cases registered by the Tasmanian Cancer 
Registry were compared with the results of the current study, only 13 previously 
unrecognised cases of PTC were identified, indicating Registry ascertainment for the 
period 1988-1998 was 93.9% complete (Figure 4.1). 
Forty patients with a malignant diagnosis underwent an initial subtotal thyroidectomy 
followed by completion thyroidectomy once malignancy was identified. Nine (4.9%) 
cases were diagnosed by FNAB cytology alone, without histopathological material being 
available for subsequent evaluation. Of 175 patients with an histopathological diagnosis 
of TC, 70 (40%) had at least one preoperative assessment using FNAB cytology (14 
benign cytology, 42 indeterminate, 12 malignant, 7 unsatisfactory and one result 
unavailable for review). Of the 42 patients with indeterminate cytological results - 
follicular lesions accounted for 24, oncocytic lesions 4, and other atypical appearances 
were reported in 14 cases. 
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During the study period the age standardized rate for thyroidectomy increased by 6.8% 
per year for females and 10.9% per year for males (p< 0.05) (Table 4.1, Figure 4.2). 
Similarly, FNAB usage increased at a rate of 66.2% per year for females and 17.6% per 
year for males (p< 0.005) (Table 4.1, Figure 4.2). During this time the median age at 
thyroidectomy and FNAB remained stable at 48 years and 49 years respectively. There 
was an 147.6% per year increase in the use of preoperative FNAB prior to thyroidectomy 
(p< 0.001) and no significant increase in thyroidectomy without prior FNAB (0.1% per 
year increase, p=0.24) (Table 4.1). In the latter part of the study period preoperative 
FNAB exhibited less restriction to lesions ultimately found to be malignant than was the 
case initially (Table 4.2, 4.3). 
The likelihood of diagnosing a PTC in any given thyroidectomy specimen increased from 
3.3% in 1988 to 7.7% in 1998 (Table 4.2). Diagnoses of PTC in patients previously 
assessed by FNAB increased by 99.7% per year (p<0.005), whilst for those in whom a 
prior FNAB was not performed the increase was 10.1% per year(p<0.05). The increase 
in PTC for patients assessed by FNAB was evident for tumours <1 cm as well as those 
>lcm diameter — although the increase was greater in the former (Table 1). Although not 
reaching statistical significance, there was also a trend (10.1% per annum) for increase in 
PTC >lcm without history of pre-operative FNAB evaluation (Table 4.1). 
To evaluate prevalence trends for incidental diagnoses of PTC, all patients identified by 
the Tasmanian Cancer Registry with PTC during the period 1978-1998 were sought for 
completion of a questionnaire regarding the preoperative likelihood of malignancy. 
There was a 63.6% increase in the diagnoses of PTC _lcm diameter in individuals with a 
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low preoperative likelihood of malignancy, and this accounted for the majority of 
increased PTC diagnoses between the time periods 1978-'91 and 1992-'98 (Table 4.4). 
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Discussion 
This study suggests an increase in the diagnosis of small PTC resulting from 
contemporary clinical practices (increased neck imaging and FNAB) is likely to account 
for the majority of the observed increase in PTC incidence (71, 230). Improvements to 
Cancer Registry case ascertainment does not account for the rise in PTC incidence. 
Whilst it is unlikely my methodology captured every eligible thyroid procedure, this 
study does provide a robust estimate of total thyroid surgical and cytological procedures 
performed in the Tasmanian population during the study period. Over this time, only 
thirteen cases of thyroid carcinoma not originally registered by the Tasmanian Cancer 
Registry were identified (Figure 4.1). Similarly, a previous review of tumours recorded 
by the Tasmanian Cancer Registry (presented in Chapter 3), determined that incorrect 
histological classification either at the Registry, or at the time of original histological 
diagnosis, occurred in less than 10% of cases (213). Thus, there is no suggestion that 
procedural changes in relation to Cancer Registry case ascertainment have resulted in 
observed PTC incidence trends. 
Thyroidectomy and FNAB cytology rates have increased by 7% per year and 49.7% per 
year respectively in Tasmania (Table 4.1). As evidenced by the increased use of FNAB in 
patients ultimately diagnosed with benign lesions and small PTC, there appears to have 
been a trend towards decreased restriction of pre-operative FNAB to patients at high a 
priori cancer risk (Table 4.2). Particularly in the later years of the study period, not only 
was cytology used more frequently, it was more likely to be used less selectively - 
preoperative cytological findings and final histology were less concordant. 
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Broader use of FNAB is further suggested by the increasing proportion of patients 
undergoing pre-operative FNAB cytology for whom the ultimate diagnosis was a benign 
lesion (Table 4.2, 4.3). It appears FNAB was initially reserved for "high" risk patients, 
but in more recent years FNAB seems to have been offered more generally to "lower" 
risk individuals. This is in keeping with promotion and acceptance of an evaluation 
protocol for thyroid nodules that recommends FNAB for the majority of thyroid nodules 
found in patients with a non-suppressed TSH (71, 75, 76, 212). 
Whilst it is not possible to directly quantify the effect of increased use of neck imaging 
(CT and ultrasonography) on the identification of "occult" PTC, there has been a 
substantial rise in the use of neck imaging since the early 1980's. Neck ultrasonography 
in particular appears to have become widely used in primary medical practice for the 
evaluation of non-specific neck symptoms and vascular conditions, as well as for 
clinically evident thyroid indications. Australian government data show the number of 
neck ultrasound procedures performed in Tasmania increased markedly between 1993 — 
1998 (Figure 4.3). 
In the context of increased use of medical imaging and contemporary medico-legal 
sensitivities it is not surprising that current trends are seen. Impalpable and 
asymptomatic thyroid nodules are a common finding when the thyroid is imaged for non-
nodular indications or evaluated at autopsy. The prevalence of PTC diagnosed 
antemortem is approximately 0.1%, versus up to 13% for occult PTC in autopsy series 
(170, 202, 205). Whilst most nodules identified by neck imaging are benign (colloid 
nodules and follicular adenomas), an important minority are PTC, the majority which are 
86 
5_1cm in diameter. Therefore increased use of neck ultrasound imaging in conjunction 
with consequential FNAB cytological evaluation could account for much of the observed 
increase in diagnoses of PTC .1cm diameter (201, 205, 210, 228, 230). 
Most studies of the natural history of such lesions have concluded these "occult" FTC 
mostly follow an indolent course and have an excellent prognosis (83, 182). However a 
proportion of incidental thyroid carcinoma are destined to become a clinically relevant. 
The study by Nam-Goong et al showed that a proportion of incidental identified PTC 
were associated with extrathyroidal extension or metastases (83). At present however, 
there is no reliable way of selecting for excision those lesions destined to produce 
clinically relevant malignancy, whilst sparing the majority of patients with indolent 
disease from an unnecessary thyroidectomy. The standard of care therefore remains 
resection of thyroid "incidentalomas" if initial cytology is suspicious for malignancy. 
The possibility of a true biological change affecting the incidence of FTC cannot be fully 
excluded by this study. The trend for increased incidence of larger (>1cm) FTC, suggests 
that improved recognition of "occult" FTC may not account for all of the observed 
incidence increase (Table 4.3). In particular, the incidence of PTC >1 cm in patients for 
whom a preoperative FNAB had not been undertaken, has also increased by 10.1% 
annually. Whilst a proportion of these tumours may have been clinically "occult", it is 
likely many were symptomatic or clinically palpable at presentation. This is supported 
by the findings presented in Table 4.4. 
Therefore, a complex mix of underlying processes is likely to have resulted in the change 
to PTC incidence observed during the latter part of the 20 th century (60, 139, 163, 170, 
202, 206). The current study suggests the increased PTC incidence is mostly due to 
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identification of "occult" PTC (greater use of ultrasonography and FNAB cytology, lower 
thresholds for thyroidectomy and heightened scrutiny during histopathological 
assessment). In addition a smaller but real increase in underlying PTC incidence may also 
have occurred. 
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Conclusions 
Over the past two decades there has been a substantial increase in the use of neck 
ultrasonography and consequently thyroid FNAB cytology to evaluate small and 
otherwise asymptomatic thyroid nodules. Thyroidectomy rates appear to have risen in 
response to increased use of FNAB and the consequential increase in reporting of 
suspicious cytology. However, the rise in incidence of PTC >lcm diameter suggests that 
a true increase in PTC incidence rates has also occurred. Given parallels between the 
overall change in PTC incidence observed in Tasmania as well as other parts of Australia 
as well as globally, the findings of the current study are likely to be of value in 
understanding the world-wide rise in PTC incidence observed in recent decades. 
-, 
Additional studies are also required to evaluate the role of established risk factors (such 
as ionising radiation and genetic susceptibility), as well as further elucidating the role of 
iodine nutrition in trends for PTC. 
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Table 4.1 	Statistical characteristics of thyroid procedures undertaken and PTC 
diagnosed in Tasmania (1988-1998) 
Subgroup 
Average 
Annual increase 
(%) 
Confidence Interval 
R2 p = 
Lower 95% Upper 95% 
Thyroidectomy (M+F) 7.0 4.1 9.9 0.77 <0.001 
Female 6.8 4.2 9.4 0.80 <0.001 
Male 10.9 1.8 20.0 0.45 0.024 
Thyroid FNAB (M+F) 49.7 37.7 61.7 0.91 <0.001 
Female 66.2 48.6 83.9 0.89 <0.001 
Male 17.6 8.9 26.2 0.70 0.001 
Thyroidectomy (M+F) (FNAB)* 147.6 107.9 187.3 0.89 <0.001 
Thyroidectomy (M+F) (no FNAB) 0.1 -0.8 2.9 0.15 0.239 
Diagnosis of PTC (M+F) 
+ 
Prior FNAB (M+F)** 99.7 39.4 160.1 0.78 0.005 
Size <lcm (M+F) ++ >100% na na na na 
Size >lcm (M+F) 63.9 9.3 118.5 0.44 0.027 
No Prior FNAB 10.1 2.5 17.6 0.71 0.014 
Size 	lcm (M+F) 10.0 -14.7 34.6 0.24 0.385 
Size >lcm (M+F) 10.1 -0.5 25.8 0.44 0.177 
*Patients undergoing thyroidectomy (partial or total) following a prior FNAB 
New (incident) cases of PTC diagnosed at histology following thyroid surgery 
** New (incident) PTC diagnosed after thyroid surgery in patients for whom an FNAB has previously been performed. 
++ No cases identified for the initial six years of study - exact percentage change per annum unable to be calculated 
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Table 4.2 	Time trends for thyroid histology and their relationship to 
preoperative FNAB cytology 
Histology Outcome 
FNAB status prior to Thyroidectomy 
1988 - 1992 1994 - 1998 
Total No FNAB FNAB Total No FNAB FNAB 
Histology - benign 
Number of cases 645 609 36 961 688 273 
Proportion of cases (%) 92.3 94.0 70.6 89.5 92.2 83.2 
Female :Male ratio 4.5 4.5 4.1 4.7 4.1 7.5 
Median age (y) 50 50 48 49 49 49 
Histology - PTC 
Number of cases 33 27 6 82 45 37 
Proportion of cases (%) 4.7 4.2 11.8 7.6 6.0 11.3 
Female :Male ratio 4.5 5.8 2 6.5 8.0 5.2 
Median age (y) 45 49 42 44 44 44 
Histology - Other TC 
Number of cases 21 12 9 31 13 18 
Proportion of cases (%) 3.0 1.9 17.7 2.9 1.7 5.5 
Female :Male ratio 1.3 1.4 1.3 1.2 0.9 1.6 
Median age (y) 45 48 41 56 74 52 
91 
Table 4.3 	Time trends for thyroid histology and their relationship to pre- 
operative cytological findings 
Histology Outcome 
Pre-operative FNAB findings 
1988 - 1992 1994 - 1998 
Histology - benign 
Number of cases 32 21 nil 8 148 99 1 46 
Proportion of cases (%) 94.2 67.8 100 91.9 75.0 11.1 88.5 
Female :Male ratio 3.6 6.0 8:0 6.8 8.9 1:0 5.3 
Median age (y) 44 50 47 49 45 17 51 
Histology - PTC 
Number of cases 1 5 1 nil 11 18 7 5 
Proportion of cases (%) 2.9 16.1 25.0 6.8 13.6 78.8 9.6 
Female :Male ratio 1:0 1.5 1:0 2.7 8.0 6.0 4.0 
Median age (y) 36 41 50 45 43 38 48 
Histology - Other TC 
Number of cases 1 5 3 0 2 15 1 1 
Proportion of cases (%) 2.9 16.1 75.0 1.3 11.4 11.1 1.9 
Female :Male ratio 0:1 1.5 0.5 3:0 1.5 0:1 0:1 
Median age (y) 41 41 67 59 52 54 59 
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Table 4.4 Preoperative suspicion of thyroid carcinoma and operative findings for 
99 cases of papillary thyroid carcinoma categorized by year of diagnosis. 
PTC Characteristics 1978 - 1984 1985 - 1991 1992 - 1998 
n (%) M . F n (%) M F n (%) M: F 
Total Cases 8 1:7 19 1:3.8 72 1:4.5 
Thyroid carcinoma unexpected* 3(37.5) 1:2 8(42.1) 1:3 32 (44.4) 1:5.4 
FTC <1.0cm 0 - 3 (15.8) 1:3 17 (23.6) 2:7.5 
FTC >3.0cm or Invasive or Metastatic 1(12.5) 1:0 4(21.1) 1:3 6(8.3) 0:6 
Thyroid carcinoma expected** 5(62.5) 0:5 10 (52.6) 1:4 38 (52.7) 1:3.8 
PTC <1.0cm 2(25.0) 0:2 2(10.5) 0:2 12 (16.7) 1:5 
PTC >3.0cm or Invasive or Metastatic 1(12.5) 0:1 4(21.1) 0:4 15 (20.8) 1:2 
Based on response to questionnaire completed by 99 patients with PTC diagnosed between 1978-1998. 
Thyroid carcinoma clinically expected preoperatively 
** 	Thyroid carcinoma not clinically expected preoperatively and identified incidentally at time of 
thyroidectomy 
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Figure 4.1 Completeness of thyroid carcinoma case ascertainment by Tasmanian Cancer Registry (1988 - 1998) 
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Figure II Trends for Thyroid Surgery and FNAB cytology in Tasmania (1988 - 1998) 
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Figure III Trends for Neck ultrasonography in Tasmania (1993 - 1998) 
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CHAPTER 5 
The Impact of Birth and Residence in Tasmania on the 
Prevalence of Benign and Malignant Thyroid Disease 
97 
Prologue 
The key questions addressed by this chapter are: 
1 	What is the prevalence of benign and malignant thyroid disease in Tasmania? 
2 	What is the prevalence of subclinical nodular thyroid disease in Tasmania 
3 	Is there evidence for an increased risk for thyroid disease based on birth and 
subsequent residence in Tasmania? 
Presentations and publications arising from this Chapter: 
Presented 
Preliminary results presented at the 49th meeting of The Endocrine Society of Australia, 
Gold Coast, Australia, 2006. 
The study described in this chapter was undertaken between 1999-2000 prior to 
introduction of community iodine prophylaxis in 2001. 
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Aim 
1 	To determine the prevalence of clinically diagnosed benign and malignant thyroid 
disease in the Tasmanian population. 
2 	To determine the prevalence subclinical thyroid nodularity in the Tasmanian 
population. 
3 	To determine if longterm residence in Tasmania is associated with an heightened 
risk for either benign or malignant thyroid disease. 
Hypothesis 
1 	More severe historical iodine deficiency in Tasmania relative to other 
Australian states should manifest as an higher rate of benign and malignant 
thyroid disease in long-term Tasmanian residents 
2 	Increasing rates for PTC diagnosis in Tasmania and other previously iodine 
deficient regions of Australia are the result of an high underlying prevalence 
of both clinical and subclinical benign thyroid disease, resulting in an 
increased likelihood of diagnosing "occult" PTC. 
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Introduction 
Factors such as genetic susceptibility iodine deficiency and ionising radiation influence 
the aetiogenesis of goitre, thyroid neoplasia and thyroid dysfunction(28, 29, 133, 136, 
206, 222). As discussed in prior Chapters, the influence of iodine nutrition on the 
pathogenesis and PTC remains poorly understood. Some studies suggest a direct 
relationship between increasing iodine nutrition and PTC incidence however, the impact 
age at exposure to iodine deficiency/sufficiency has on PTC risk remains unclear(28, 29, 
131, 165, 166, 169). 
Iodine deficiency may modify the clinical presentation of benign thyroid disease, thereby 
increasing the prevalence of goiter and increase the likelihood of diagnosing "occult" 
PTC by (45, 50, 57). Greater use of ultrasonography and surgery for multinodular goiter 
evaluation and treatment are likely to accentuate this in iodine deficient populations (71, 
173). 
In this Chapter an health survey and ultrasonographic study was undertaken to determine 
the prevalence of both subclinical and previously diagnosed thyroid disease in the 
Tasmanian population. Specific attention is given to the influences of birth year, birth 
place, and place of long-term residence on the development of thyroid disease to 
determine if early life exposure to Tasmanian environmental factors such as iodine 
nutrition accounts for the contemporary pattern of TC incidence in Tasmania. 
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Subjects and Methods 
Following approval of the Royal Hobart Hospital Research Ethics Committee a random 
sample of 10 000 adults registered on the Tasmania electoral role in the year 1999 were 
invited to complete a health questionnaire regarding thyroid disease and related risk 
factors. The survey was conducted in late-1999 with 5774 respondents available for 
assessment. 
Of these, 463 age stratified respondents were selected at random for invitation to undergo 
thyroid ultrasonography. Of these, 205 agreed to participate and underwent imaging. 
Thyroid evaluation was performed by experienced sonographers using a 7.5 mhz 
transducer. Scanning was undertaken with the subject supine and the neck 
hyperextended. Thyroid volume (m1) was calculated using the formula: width (cm) x 
length (cm) x thickness (cm) x 0.479 with the volume of each lobe summed. Goitre was 
defined as thyroid volume greater than 18.1m1 in males and 13.0m1 in females(24). 
Whilst less sensitive than comparison based on body surface area normative criteria, 
insufficient anthropomorphic data was available to undertake this calculation. The level 
of early life exposure to the Tasmanian environmental factors such as iodine deficiency 
was indirectly assessed by two criteria 1) birthplace Tasmania and <1 year lifetime 
residence elsewhere (High exposure), 2) birthplace not Tasmania and >10 years lifetime 
residence outside Tasmania (Low exposure). 
In addition, patients identified by the Tasmanian Cancer Registry with a diagnosis of 
PTC during the period 1978-1998 (n=180, Female:Ma1e=3.5, Age at diagnosis 46.4±1.1) 
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were sought to determine place of birth and long-term residence. Of these, 99 patients 
(Female:Male=4.8, Age at diagnosis 44.5±1.0) were living, contactable and consented to 
provide this information. 
Normally distributed variables were analysed using the Student's t-test. Where 
appropriate, numerical data is presented as Mean ± Standard Error of Mean (SEM). 
Univariate and multivariate analyses were performed using GraphPad InStat version 3.0a 
for Macintosh, GraphPad Software, San Diego California USA. 
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Results 
Of 5774 survey respondents (male 2746, female 3028) a past history of TD was reported 
by 580 (10.0%), (male 106 (3.9%) and female 474 (15.7%)) (Table 5.1). An history of 
thyroid carcinoma was described by 35 (0.6%), (male 10 (0.4%) and female 25 (0.8%)). 
Goitre was reported by 241(4.2%) (male 47(1.7%), female 194(6.4%)) and an history of 
thyroid imaging by 238 (4.1%). Thyroxine use was reported by 2.3% of survey 
respondents (male 12 (0.4%), female 123 (4.1%)); of whom a past history of thyroid 
surgery and/or goiter was described by 59.3%. Hyperthyroidism was reported by 167 
(2.9%), (male 34 (1.2%), female 133 (4.4%)) (Table 5.1). Thyroid surgery was described 
by 162(2.8%) (male 29(1.1%), female 133(4.4%)) of whom, 76 (46.9%) also described 
an history of thyroid imaging. 
Compared to individuals born and resident life-long in Tasmania (n =3150, F:M ratio = 
1.2, age = 51.5±0.3 years), those not born in Tasmania and spending more than ten years 
elsewhere (n=1319, F:M ratio 1.0, age 58.210.4 years, mean years lived outside 
Tasmania 33.2±0.4 years) had a significantly (p<0.05) lower prevalence of thyroid 
problems overall, and goitre in particular (Table 5.2). Thyroid cancer was non-
significantly increased amongst individuals born and life-long resident in Tasmania 
(0R=1.3, p=0.751) (Table 5.2). 
Ultrasonography revealed thyroid nodules in 43.4% of individuals undergoing 
ultrasonography (Table 5.2, 5.3). Nodules were at least as frequent in those born and 
long term resident in Tasmania as for individual born elsewhere (Table 5.2). Many 
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patients (88.8%) with thyroid nodules on ultrasound did not report a previously 
diagnosed history of thyroid disease (Table 5.4). 
Stratification of thyroid disease by birth cohort to reflect likelihood of iodine deficiency 
in childhood/ adolescence is presented in Table 5.5. The birth cohort 1925-'40 who were 
born and resident in Tasmania can be considered relatively iodine deficient in childhood/ 
adolescence. Childhood/ adolescent, iodine nutrition had improved and was relatively 
similar irrespective of birthplace and subsequent residence for the 1955-'70 birth cohort 
due to the nationwide effect of iodophors on iodine nutrition. In a model adjusting for 
age and gender, only history of "any thyroid disease" (p=0.002), goitre (p=0.002) and 
hyperthyroidism (p=0.024) were significantly associated with birth and residence in 
Tasmania for birth cohort 1925-'40. No significant association between thyroid disease 
and birth and residence in Tasmania was found for birth cohort 1955-'70 (Table 5.5). 
In a sub-study of an additional 99 PTC patients for whom information regarding place of 
birth and subsequent residence was available, 57.6% were born in Tasmania and had 
never resided elsewhere for more than 12 months. There was no correlation between 
PTC size and patient demographic profile, with 18 of 36 (50.0%) PTC _I cm associated 
with dominant residence in Tasmania compared to 39 of 62 (62.9%) tumours >1 cm 
diameter (ns). 
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Discussion 
This study indicates that thyroid disorders (including their investigation and treatment) 
are common, occurring with prevalence similar to that of health problems such as 
diabetes and hypertension (Table 5.1). These findings are similar to those from a large 
Norwegian population survey of thyroid disease in which hyperthyroidism was reported 
by 2.5% and 0.6% of females and males respectively and hypothyroidism in 4.8% and 
0.9% respectively, and goitre described by 2.9% of females and 0.4% of males(231). 
Tasmania's history of relatively more pronounced iodine deficiency appears responsible 
for the increased likelihood of thyroid disease and thyroid surgery amongst long-term 
residents born prior to the correction of iodine deficiency. Interestingly, subclinical 
thyroid nodularity was frequent irrespective of birth place and place of dominant lifetime 
residence in the 1960's. Similarly, long-term Tasmanian residence did not confer a 
significantly elevated risk for malignant thyroid neoplasms. 
The potential for thyroid ultrasonography to reveal "occult" thyroid nodularity is well 
recognised and highlighted by the current study(41, 60, 173, 232). In accordance with 
prior research, the prevalence of thyroid nodules on ultrasound was approximately ten-
fold higher than that of self reported thyroid disease, with age the key predictor for their 
presence (Table 5.2, 5.3) (50, 57, 60). This confirms the anticipated divergence between 
the absolute risk for nodular thyroid disease (based on ultrasonography) and the 
likelihood of clinically diagnosed thyroid nodularity. Notably, whilst the former appears 
uninfluenced by place of birth and residence, the later was increased amongst individuals 
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reporting prolonged residence in Tasmania (particularly in their childhood during the 
iodine deficient era prior to the 1950's). 
Whilst the current results supports the well established link between iodine deficiency 
and goitre (simple, multinodular and functionally autonimous), they do not show a 
significant association between the absolute risk for development of nodular thyroid 
disease / neoplasia and iodine nutrition. Age as opposed to unique environmental factors 
appears to be the key determinant of absolute prevalence of thyroid nodularity. 
Thyroid carcinoma was non-significantly higher for in individuals born and resident long 
term in Tasmania versus those born elsewhere. However, there was no convincing 
evidence for a specific environmental exposure (such as iodine nutrition) to explain PTC 
incidence trends. The birth cohort born after introduction of iodine 
supplementation/iodophors appear to be at no greater risk of thyroid disease irrespective 
of place of birth residence(214, 216). This suggests that the pathogenesis of PTC is not 
influenced by the absolute increase (greatest in Tasmania) in iodine nutrition. However, 
the relative comparison methodology used by this study does not account for possible 
shared exposure to common PTC risk factors affecting both those born and resident long-
term in Tasmania as well as those migrating to Tasmania from elsewhere. 
The influence of early life iodine nutrition on thyroid neoplasia could be underestimated 
by this study if: a) the historical differential in severity of iodine deficiency between 
Tasmania and the other south-eastern Australian states was less pronounced than 
generally assumed, b) the assumption that migrants to Tasmania derived predominantly 
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from relatively iodine sufficient regions is incorrect (eg. post second world war migration 
from iodine deficient regions of Europe), and c) common levels of iodine nutrition across 
Australia in more recent years have modified the impact any difference in childhood 
iodine nutrition may have had on nodular thyroid disease and thyroid volume. It is also 
notable that whilst the relative increase in TC incidence is highest in previously iodine 
deficient regions of Australia, the absolute incidence of PTC in these areas was lower at 
baseline. Hence iodine repletion via milk during the 1960's-1980's may have relatively 
affected PTC incidence more in previously deficient areas. 
Whilst the results from the current study are prone to bias (self-reported medical history 
is influenced by the disease in question and the temporal proximity of disease occurrence 
to time of survey), thyroid diseases have been shown to be moderately well reported by 
self-administered questionnaire compared to in-person interview. In the study by Brix et 
al the self-reported diagnosis of hyperthyroidism and hypothyroidism were both 98% 
although the specificity was mediocre at 57% and 67% respectively(233). Similarly, an 
assessment of self-reported cancer incidence in the California Teachers Study found the 
concordance for thyroid cancer between survey results and cancer registry data was at 
least 90% sensitive and specific (234). 
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Conclusions 
This study confirms that neck imaging has a great capacity to increase identification of 
subclinical nodular thyroid disease and that residence in a region with an history of 
iodine deficiency increases the likelihood of neck imaging and surgery for benign 
conditions. Furthermore, injudicious use of thyroid ultrasonography in patients without 
clinical suspicion of thyroid disease could be considered a "risk factor" for thyroid 
surgery and consequently the diagnosis of prevalent, yet clinically not apparent, papillary 
microcarcinoma. 
A direct link between iodine nutrition and the pathogenesis of PTC in Tasmania is not 
suggested by this study. However, further evaluation of the role played by other 
established risk factors such as ionising radiation and genetic susceptibility will be of 
value. 
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Table 5.1 Thyroid and health profile of study participants 
Characteristics 
All questionnaire 
respondents 
Ultraso und sub- 
St udy 
Male Female Male Female 
Number of Subjects n=2746 n=3028 n=76 n=129 
Age (yrs) 54.7±0.3 52.5±0.3 55.7±1.7 50.2±1.0 
Any past history thyroid disease (%) 3.9 15.7 2.6 13.2 
Goitre (%) 1.7 6.4 1.3 5.4 
Thyroid surgery (%) 1.1 4.4 0.0 2.3 
Thyroid cancer (%) 0.4 0.8 0.0 0.0 
Thyroid scan (%) 1.7 6.3 0.0 8.5 
Hyperthyroid (%) 1.2 4.4 1.3 3.9 
Hypothyroid (%) 1.1 5.8 1.3 3.9 
Taking thyroxine (%) 0.4 4.1 0 2.3 
Family History thyroid disease (%) 10.4 21.1 15.8 27.1 
Hypertension (%) 24.3 27.9 18.4 20.9 
Diabetes (%) 5.3 4.5 8.3 3.9 
Hypercholesterolaemia (%) 16.7 13.1 13.2 9.3 
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Table 5.2 	Prevalence of clinical and subclinical nodular thyroid disease for 
questionnaire respondents undergoing thyroid ultrasonography 
Ultrasonographic 
Characteristics 
Age 18-44 years Age 45-64 years Age 65-85 years 
Past 
History 
TD* 
No Past 
History 
TD** 
Past 
History 
TD* 
No Past 
History 
TD** 
Past 
History 
TD* 
No Past 
History 
TD** 
Number of subjects (n----) 6 62 8 82 5 42 
Female / Male ratio 6/0 1.8 7.0 2.4 4.0 0.6 
Age (yrs) 42.6±0.6 37.9±0.6 53.0±2.4 53.0±0.6 72.2±2.1 71.0±0.6 
Thyroid volume (m1) 6.0±2.3 10.2±0.7 7.3±1.6 9.8±0.6 10.5±2.1 11.8±0.9 
Nodules (total) (%) 16.7 30.7 50.0 43.9 80.0 57.1 
Solitary nodule (%) 16.7 12.9 12.5 12.2 0.0 16.7 
Multiple nodules (%) 0.0 17.7 37.5 31.7 80.0 40.5 
Nodule size 
- <lcm (%) 16.7 27.4 37.5 37.8 60.0 47.6 
- 1-2cm (%) 0.0 9.7 12.5 18.3 20.0 26.2 
- >2cm (%) 0.0 0.0 0.0 1.2 0.0 4.8 
Any past history of thyroid disease (goitre, nodules, surgery, thyroid dysfunction or imaging) reported by patient 
No past history of thyroid disease reported by patient 
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Table 5.3 	Prevalence of thyroid disease based on place of birth and childhood residence for 
questionnaire respondents and subjects undergoing thyroid ultrasonography 
Characteristic Female Male 
Born inTas. 
<ly 
Elsewhere** 
Not Born in 
Tas.>10y 
Elsewhere" 
p= 
Born in Tas. 
<ly 
Elsewhere** 
Not Born in 
Tas. >10y 
Elsewhere" 
p= 
Questionnaire 
Number of subjects (n=) n=1727 n=650 n=1423 n=669 
Age (yrs) 51.1+0.4 56.7+0.6 <0.001 51.9±0.5 59.6±0.6 <0.001 
Years lived away Tas. (yrs)* - 32.3±0.6 na - 34.0±0.6 na 
Any past thyroid disease (%) 16.6 13.5 0.082 4.3 2.5 0.066 
Goitre (%) 7.4 4.5 0.013 2.5 0.7 0.013 
Thyroid surgery (%) 4.5 3.8 0.547 1.3 0.7 0.404 
Thyroid cancer (%) 0.9 0.6 0.719 0.4 0.4 0.930 
Thyroid scan (%) *** 5.6 6.6 0.410 1.3 1.5 0.928 
Hyperthyroid (%) 4.6 2.9 0.091 1.1 1.2 0.886 
Hypothyroid (%) 5.7 6.2 0.770 1.2 0.7 0.481 
On thyroxine (%) 3.9 4.0 0.944 0.6 0.3 0.635 
Family History TD (%) AA 23.6 14.5 <0.001 11.1 9.0 0.157 
Ultrasonography 
Number of subjects (n=) n=71 n=32 n=38 n=20 
Age (yrs) 47.7+1.3 58.0+2.0 <0.001 52.8±2.6 61.8±3.1 <0.001 
Years lived away Tas. (yrs)* - 32.9±2.5 na - 35.0±3.7 na 
Thyroid volume (m1) 8.6±0.6 9.7±0.8 12.7±0.8 11.2±1.2 
Goitre (%) 14.1 18.8 0.756 13.2 15.0 0.847 
Nodules (total) (%) 46.5 62.5 0.196 28.9 40.0 0.577 
Solitary nodule (%) 11.3 12.5 0.857 13.2 15.0 0.847 
Multiple nodules (%) 35.2 50.0 0.230 15.7 25.0 0.618 
Nodule size 
- <lcm (%) 39.4 56.3 0.169 26.3 40.0 0.440 
- 1-2cm (%) 15.5 25.0 0.381 10.5 10.0 0.950 
- >2cm (%) 2.8 3.1 0.931 0 0 na 
Number of years of residence away from Tasmania 
Born in Tasmania and never lived elsewhere for more than 12 months 
Not born in Tasmania and has lived elsewhere for more than 10 years 
History of ever undergoing any thyroid imaging reported by patient 
AA 	Family history of thyroid disease (TD) reported by patient 
ns 	p values >0.1 reported as ns 
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Table 5.4 	Prevalence of thyroid disease based on age for questionnaire respondents 
and subjects undergoing thyroid ultrasonography 
Characteristics Age 18-44 years Age 45-64 years Age 65-85 years 
Male Female Male Female Male Female 
Questionnaire 
Number of subjects (n=) n=808 n=1065 n=1012 n=1089 n=924 n=869 
Age (yrs) 33.7±0.3 33.2±0.2 55.0±0.2 54.7±0.2 72.7±0.2 73.4±0.2 
Any past thyroid disease (%) 2.5 7.6 3.2 16.8 5.8 24.2 
Goitre (%) 1.7 3.5 1.3 6.3 2.2 10.1 
Thyroid surgery (%) 0.7 1.7 0.8 5.3 1.6 6.6 
Thyroid cancer (%) 0.4 0.8 0.3 1.0 0.4 0.7 
Thyroid scan (%)** 1.1 3.9 2.2 6.9 1.7 8.5 
Hyperthyroid (%) 1.1 2.8 0.9 3.9 1.7 7.0 
Hypothyroid (%) 0.5 3.4 1.4 6.2 1.3 8.2 
On thyroxine (%) 0.0 1.9 0.4 5.2 0.9 5.3 
Family History TD (%)*** 11.4 20.6 10.1 23.8 10.0 18.4 
Born in Tasmania (%)*** 80.1 79.6 65.6 68.2 64.3 64.3 
Ultrasonography 
Number of subjects (n=) n=22 n=46 n=26 n=64 n=28 n=19 
Age (yrs) 37.3±1.1 38.8±0.7 54.4±0.9 52.4±0.7 71.4±0.7 70.7±0.9 
Thyroid volume (ml) 13.1±1.3 8.2+0.6 11.7±1.2 8.8±0.7 12.4±1.1 10.5±1.1 
Goitre (%) 13.6 10.9 15.4 12.5 17.9 26.3 
Nodules (total) (%) 22.7 34.8 19.2 56.3 50.0 73.7 
Solitary nodule (%) 13.6 15.2 7.7 14.1 17.9 10.5 
Multiple nodules (%) 9.0 19.6 11.5 42.2 32.1 63.2 
Nodule size 
- <lcm (%) 22.7 30.4 19.2 46.9 42.9 57.9 
- 1-2cm (%) 4.6 10.9 3.9 23.4 25.0 26.3 
- >2cm (%) 0.0 0.0 0.0 1.6 0.0 10.5 
Family history of thyroid disease (TD) reported by patient 
History of ever undergoing any thyroid imaging reported by patient 
Born in Tasmania and never lived elsewhere for more than 12 months 
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Table 5.5 	Age and birth cohort stratified prevalence of thyroid disease based on place of 
birth and childhood residence for questionnaire respondents and subjects 
undergoing thyroid ultrasonography 
Characteristic Birth Years 1955 --`70 Birth Years 1925 -`40 
Born in Tas. Not Born in p= Born in Tas. Not Born in p= 
<ly Elsewhere Tas. >10y <ly Elsewhere Tas. >10y 
Elsewhere Elsewhere 
Questionnaire 
Number of subjects (n=) 775 229 - 895 512 - 
Age (yrs) 37.1+0.2 37.80.3 0.06 66.5+0.2 67.1+0.2 0.032 
F/M 1.3 1.4 0.649 1.0 0.8 0.052 
Years lived away Tas. (yrs) - 25.8+0.5 na - 36.5+0.7 na 
Any past thyroid disease (%) 5.0 10(4.4 0.813 17.1 8.6 <0.001 
Goitre (%) 2.6 2.6 0.974 8.3 2.7 <0.001 
Thyroid surgery (%) 1.3 1.3 0.982 4.5 1.6 0.006 
Thyroid cancer (%) 0.5 0.4 0.881 0.2 0.2 0.912 
Thyroid scan (%)** 2.5 3.5 0.533 5.1 3.9 0.357 
Hyperthyroid (%) 1.9 1.3 0.731 4.8 1.8 0.006 
Hypothyroid (%) 2.3 2.2 0.902 5.3 4.1 0.402 
On thyroxine (%) 1.3 0.9 0.870 3.5 1.8 0.092 
Family History TD (%)*** 15.9 12.2 0.211 18.3 10.2 <0.001 
Ultrasonography 
Number of subjects (n=) 43 7 19 22 
Age (yrs) 38.5+0.6 41.8+1.1 0.042 65.8+1.2 67.9+0.7 0.124 
F/M 1.8 6.0 0.518 0.7 1.8 0.287 
Years lived away Tas. (yrs) - 25.1+4.2 na - 37.6+3.7 na 
Goitre (%) 11.6 0.0 0.786 21.1 18.2 0.817 
Nodules (total) (%) 32.6 42.9 0.677 52.6 63.6 0.693 
Solitary nodule (%) 11.6 14.3 0.841 15.8 13.6 0.849 
Multiple nodules (%) 20.9 28.6 0.651 36.8 50.0 0.595 
Nodule size 
- <lcm (%) 32.6 42.9 0.677 42.1 59.1 0.440 
- 1-2cm (%) 7.0 14.3 0.464 21.1 18.2 0.817 
- >2cm (%) 0.0 0.0 na 10.5 4.6 0.895 
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Figure 5.1 Prevalence of thyroid nodules by age (10 year age categories) 
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CHAPTER 6 
An indirect assessment of the role of ionising radiation in the 
genesis of contemporary PTC incidence trends 
115 
Prologue 
The key questions addressed by this chapter are: 
1 	Is there molecular genetic evidence (RET/PTC1 rearrangement) for past ionizing 
radiation exposure in priming Tasmanian PTC incidence trends? 
2 	What are the prevalence trends for RET/PTC1 in Tasmanian PTC? 
Presentations and publications arising from this Chapter: 
Presented 
Preliminary results resented at the International Congress of Endocrinology (ICE 2000), 
Sydney, Australia, 2000. 
Published 
Burgess JR, Skabo S, McArdle K, Tucker P. Temporal trends and clinical correlates for 
the ret/PTC mutation in papillary thyroid carcinoma. ANZ J Surg. 2003; 87: 31-5. 
In accordance with the criteria for submission of thesis by previously published research, 
Chapter 6 is based on the above cited publication. 
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Aim 
To determine if evidence exists for past ionizing radiation exposure as a cause for 
increasing PTC incidence. 
Hypothesis 
1 	Childhood exposure to radioiodine during the 1950's and early 1960's contributes 
to contemporary PTC incidence trends. 
2 	Time trends for the RET/PTCI rearrangement may provide an indirect indication 
of past ionizing radiation exposure as an aetiological factor in contemporary PTC 
incidence trends. 
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Introduction 
Ionizing radiation is the best characterized aetio logic factor for thyroid neoplasia (134, 
136, 206, 235). Benign and malignant tumours are predisposed by prior thyroid 
irradiation. PTC is the most frequent malignant sequel of thyroidal irradiation (133, 136, 
206). There appears to be no threshold below which thyroid tumorigenesis is not 
increased, but the risk is greatest when the exposure occurs during childhood, particularly 
during the early years of life (135-137, 206). Although exposure in early childhood 
confers the greatest risk, disease may not arise until adulthood because the latency 
between exposure and cancer presentation can exceed three decades (133, 136, 137, 209). 
Both external beam irradiation and ingestion of radioiodines in childhood are associated 
with PTC development(134, 136). In the case of radioiodine, even low levels of exposure 
from nuclear fallout can marginally increase long-term thyroid cancer risk (133, 136, 
137, 209). It has been estimated that fallout radioiodines from Chernobyl increased 
thyroid cancer incidence as far away as Connecticut in the USA (139). When the low 
baseline incidence of PTC is considered in conjunction with the size of fallout-exposed 
populations, significant relative increases in PTC incidence are a potential long-term 
consequence of exposure to low levels of radioiodine fallout. 
A number of genes are linked to the development of PTC, including RAS, RET/PTC, 
TRK, BRAF, p5.3, MET and PAX8 (49, 109, 110, 115-117). Activating mutations 
involving RET, a proto-oncogene encoding a receptor tyrosine kinase, can arise following 
thyroidal irradiation (121, 124). Fusion of RET to the promoter region of an unrelated 
gene gives rise to mutations collectively termed RET/PTC rearrangements (119, 130). 
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The most prevalent of these are RET/PTC1 and RET/PTC3 (119, 126, 127). Both 
mutations result from inversions involving the long arm of chromosome 10 (121, 124, 
130). High levels of radioiodine fallout following the Chernobyl accident produced an 
early and overt rise in PTC, which was associated with the RET/PTC3 rearrangement 
(115, 121, 130). However, subsequent studies have also shown RET/PTC1 to be 
associated with PTC developing after a long latency(>10 years) from the time of 
radiation exposure (115, 124, 130). 
Therefore, the RET/PTC1 rearrangement may occur at higher frequency in thyroid 
neoplasms arising after exposure to ionizing radiation, particularly in tumours developing 
following a long latency after irradiation (115, 121, 124, 236). The RET/PTC1 
rearrangement has also been associated with tumour behaviour and prognosis. Some 
studies have suggested an association with a relatively benign clinical pattern of disease 
(111, 119, 129, 130). 
The influence of past exposure to radioiodine and diagnostic X-rays on contemporary 
Australian PTC incidence trends is difficult to establish given the absence of exposure 
data. Although RET/PTC1 is not specific to PTC arising after radiation exposure, 
prevalence trends for RET/PTC1 in PTC may provide insights into the role of past 
ionizing irradiation in the recent rise in national PTC incidence(115, 124). 
In this chapter temporal trends and the clinicopathological associations for RET/PTC1 
rearrangement in PTC diagnosed in Tasmania during the years 1978-1998 are assessed. 
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Subjects and Methods 
Following approval from the Tasmanian Cancer Registry Data Release Committee and 
the Royal Hobart Hospital Research Ethics Committee, all cases of PTC recorded by the 
Registry during the period 1978-1998 were identified and tissue samples sought for 
analysis. 
A study sample of 98 cases, representing all cases of PTC diagnosed during the even 
numbered years from and including 1978-1998, was defined. Pathology laboratories 
around Tasmania were contacted and 62 paraffin-embedded tumour samples were 
located. The histology of each sample was reviewed by two histopathologists to confirm 
accuracy of the original diagnosis (213). 
Ten tissue sections of 5 1.1m thickness were cut from representative areas of each paraffin-
embedded tissue block. Samples were deparaffinized by a 10-min incubation with xylene 
followed by a two-stage 100% ethanol wash. Deparaffinized samples then underwent an 
overnight (16-h) protease tissue digestion using the DNeasyTM Tissue Kit (Qiagen, 
Valencia, CA, USA) standard -protocol. The RNA and DNA were coextracted from 
digested samples using the DNeasyTM Tissue Kit (Qiagen) protocol. An additional on-
column DNAase digestion was then used to ensure that the eluted material was free from 
DNA contamination. 
Reverse transcription-polymerase chain reaction (RT-PCR) for RET/PTC1 was 
performed using the One-Step RT-PCR Kit (Qiagen) reagents and standard protocol. The 
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RNA from the TPC-1 cell line was used as the positive control. A negative control (H20) 
was included for each primer pair in every RT-PCR run. The primers used to detect the 
RET/PTC1 rearrangement were as described by Nikiforov et al. (5'- 
GCTGGAGACCTACAAACTGA-3' (nucleotides 425-443) and 5'- 
GTTGCCTTGACCACTTTTC-3' (nucleotides 661-685)) (121). Overall RNA integrity 
was assessed by RT-PCR using primers for human hypoxanthine 
phosphoribosyltransferase (5'-CCTGCTGGAT-TACATCAAAGCACTG-3'(nucleotides 
316-340) and 5'-CCTGAAGTATTCATTATAGTCTCAAGG-3' (nucleotides 661-685)] 
(236). 
One microgram of total RNA was used in each reaction. Reverse transcription was 
carried out at 50°C for 30 min followed by a 95°C, 10-min denaturation step. 
Amplification consisted of 42 cycles of denaturation at 94°C for 45s, annealing at 56°C 
for 1 min, followed by a final 10-min extension step at 72°C. 
The RT-PCR products were separated by electrophoresis on agarose gel and visualized 
using the ethidium bromide technique prior to photographic documentation (Fig. 6.2). 
The identity of products positive for hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) and RET/PTC1 and each of the positive controls was confirmed by sequencing 
(ABI Prism DNA sequencing kit and ABI PRISM 377 DNA sequencer; Applied 
Biosystems, Foster City, CA, USA). 
In addition, patients identified by the Tasmanian Cancer Registry with a diagnosis of 
PTC during the period 1978-1998 (n=180, Female:Ma1e=3.5, Age at diagnosis 
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46.4±1.1years) were sought to determine history of past head and neck irradiation. Of 
these, 99 patients (Female:Male=4.8, Age at diagnosis 44.5±1.0years) were living, 
contactable and consented to provide this information. 
Data were analysed using the Student's t-test for normally distributed variables and the 
chi-squared test for non-parametric data. Where appropriate numerical data are presented 
as mean ± SD. 
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Results 
The RET/PTC1 mutation was found in 26 (63%) tumours. Forty-three per cent of male 
patients and 68% of female patients were positive. The mean age at diagnosis for 
RET/PTC/-positive and RET/PTC/-negative tumours was 46.5 ± 15.46 and 
41.9 ± 13.45 years, respectively. The RET/PTC1 mutation was significantly associated 
with larger tumour size (Table 6.1). The RET/PTC1 mutation was not associated with an 
adverse prognosis (Table 6.1). 
The prevalence of tumours positive for RET/PTC1 remained stable over the study period 
(Table 6.1). Tumours positive for RET/PTC1 did not exhibit birth year or diagnosis year 
clustering (Table 6.1;Fig. 6.3). Similarly, RET/PTC1 positivity was not associated with 
other clinicopathological characteristics such as presence of multinodular goitre, 
lymphocytic infiltration, tumour multicentricity or PTC histological subtype (Table 6.1). 
Of the 99 PTC patients who provided information regarding head and neck irradiation, 4 
(4.0%) had a past history of this. Two cases related to treatment of haematological 
malignancies, one for naevus, and the fourth for a brain tumour. Of these, only one (the 
naevus) was associated with childhood radiotherapy. 
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Discussion 
In comparison with studies undertaken in other countries, this study identified a relatively 
high prevalence for the RET/PTC1 re-arrangement in Tasmanian PTC specimens (130). 
However, it is consistent with the findings previously reported by Chua et al. who 
described a prevalence of 55% for RET/PTC1 in tumours treated at a. Sydney teaching 
hospital (237). However, another Australian study by Learoyd et al. also studied this 
issue and reported a prevalence for RET/PTC1 of 8% (120). 
Chua et al. also studied PTC from New Caledonia and found a similar frequency of the 
RET/PTC1 rearrangement (70%) compared to that observed in NSW (85%) (237). This 
is notable given the high rate of PTC incidence New Caledonia (237, 238) . One could 
speculate that tumours from New Caledonia might have a higher rate of the RET/PTC1 
rearrangement than Australian tumours due to the potential for higher levels of past 
exposure to radio-iodine fallout (149). The failure to find a difference between these 
populations suggests either: (i) any difference in exposure of the New Caledonian 
population relative to that of NSW is not reflected by RET/PTC1 prevalence; (ii) the high 
prevalence of RET/PTC1 in NSW samples may indicate a role for past ionizing 
irradiation in this Australian population; or (iii) RET/PTC1 is of little or no value as a 
radiation signature. 
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Iodine deficiency increases thyrocyte uptake of radioiodines such as 1131, potentially 
increasing the likelihood of subsequent neoplasia (144). Mild-to-moderate iodine 
deficiency affected Tasmania as well as much of coastal Victoria, New South Wales and 
southern Queensland prior to the early 1960s (214, 225). The current rise in PTC 
incidence in Australia has been most marked for the population residing on Australia's 
eastern seaboard, particularly those regions with a history of iodine deficiency (213, 228). 
Prior to the Universal Test Ban Treaty of 1962, atmospheric nuclear weapons testing 
during the 1950s and early 1960s resulted in numerous episodes of fallout throughout 
Australia (Figure 6.1). Although direct human exposure to radioiodine from 
environmental contamination of air, soil and water is likely to have been negligible, 
cows' milk is recognised as a vector for radioiodine entering the food chain (144). In 
Australia, contamination of this food source by radioiodine was documented by Van 
Middlesworth and Melick in the 1950s-1960s. Their research found that episodes of 1131 
fallout affected grazing livestock in South Eastern Australia (147, 239). 
Evidence for a relationship between RET/PTC1 prevalence and birth cohort was sought 
in the present study (Table 6.1). Although exposure of the Australian population to low 
levels of radioiodine fallout can be inferred from the available data (Figure. 6.1), the 
current findings do not demonstrate an overt relationship between contemporary PTC 
incidence trends and the occurrence of RET/PTCI rearrangements (147, 239). 
When assessing the possible aetiological role of a risk factor in individual cases of 
disease, proof of causation is virtually impossible to establish in the absence of either a 
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direct or surrogate measure of past exposure to that risk factor. While not excluding 
ionizing radiation of the Australian population during the 1950s and early 1960s as a 
cause for the contemporary rise in PTC incidence, clear support for this hypothesis is not 
provided by the current study. Nonetheless, this is the first study to specifically examine 
temporal trends for PTC, and it shows a stable prevalence for RET/PTC1 despite a 
concurrent rise in PTC incidence. 
The present study shows a significant clinicopathological association for the RET/PTC1 
rearrangement. Tumours positive for the RET/PTC1 rearrangement were of larger size 
and more likely to exhibit lymph node metastases than those without the mutation. 
However, this trend was not associated with an increased risk for mortality. These 
observations are in keeping with the existing literature that suggests that RET/PTC1 does 
not confer heightened tumour aggressiveness (130). 
The ret/PTC 1 rearrangement appears to be a relatively early event in PTC 
development(130). This could explain the apparent contradiction of the rearrangement 
being common in both "occult" papillary microcarcinoma, radiation induced PTC and 
follicular adenomas(130). In each case, the early events that initiate tumor formation 
may involve ret/PTC 1, but tumour progression requires accrual of additional oncogenic 
mutations. Thus, if RET/PTC1 positive tumours acquire concurrent mutations, such as 
inactivation of the p53 tumour suppressor gene, a more aggressive phenotype may 
develop. 
The success of RT-PCR is greatly affected by amplicon size (130, 237). The greater the 
size, the greater the chance of false negative results due to sample degradation during 
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RNA extraction. This is particularly so when RT-PCR is performed on RNA derived 
from paraffin-embedded tissue samples. In the study by Learoyd et al., which reported an 
8% RET/PTC1 prevalence, the amplicon was substantially larger than that sought by the 
primer set used both in the present study and that of Chua et al (120, 237). Thus 
methodological factors are likely account for the divergent findings of these three 
Australian studies. 
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Conclusions 
This is the first study to map time trends for the prevalence of RET/PTCI relative to PTC 
incidence patterns. There was no clear relationship between PTC incidence trends and 
RET/PTC1 prevalence to suggest ionising irradiation was a dominant factor in the 
genesis of recent PTC incidence trends. Whilst in some circumstances the RET/PTC1 
rearrangement might be an indirect indication of past radiation damage, it may not be 
sufficiently specific to be considered a radiation signature. However, the absolute 
prevalence of RET/PTC1 (63%) is greater than that reported in many prior studies and is 
consistent with levels found in irradiated populations. Further assessment of past 
radiation exposure using alternate methodologies is required. 
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Table 6.1 	Clinicopathological correlates of RET/PTC1 positive papillary thyroid 
carcinoma diagnosed in Tasmania between 1978 and 1998 
Characteristic RET/PTC1 (+) 
(n) 
RET/PTC1 (-) 
(n) 
Odds ratio 
(95% CI) 
P value 
26 15 
Total (n=) 
13 (50%) 6 (40%) 1.5 (0.6-2.6) 0.746 
Age? 45 years 
11(42%) 5(33%) 1.3 (0.6-3.0) 0.742 
Multinodular goitre 
9 (35%) 8 (53%) 0.5 (0.1-1.7) 0.328 
Lymphocitic thyroiditis 
3(12%) 2 (13%) 0.9 (0.1-5.8) 1.000 
Sclerosing variant 
8(31%) 2 (13%) 2.9 (0.5-16.0) 0.277 
Follicular variant 
5 (19%) 3 (20%) 1.0 (0.2-4.7) 1.000 
Multicentric tumour 
1(3.9%) nil 1.8 (0.1-48.0) 1.000 
Family history of PTC 
7 (27%) 1 (7%) 5.2 (0.6-47.0) 0.220 
Extra-thyroid invasion 
5 (19%) 1(7%) 3.3 (0.4-32.0) 0.388 
Metastases present 
2(8%) 3 (20%) 0.3 (0.1-2.3) 0.337 
Death<1 year post Dx 
7(27%) 8 (53%) 0.3 (0.1-1.2) 0.108 
Size < 1.0cm 
19 (73%) 7(47%) 3.1 (0.8-12 0.108 
Size >lcm 
13 (50%) nil 31(1.7-570) 0.001 
Size >2 
11(42%) 7 (47%) 0.8 (0.2-3.0) 1.000 
Diagnosed < 1994 
15 (58%) 8 (53%) 1.2 (0.3-43.0) 1.000 
Diagnosed? 1994 
CI - confidence interval 
Death<1 year post Dx - death within one year of PTCdiagnosis 
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Figure 6.1 	Strontium-90 fallout in Hobart, Tasmania 1958-1990 
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Data from the Fallout Measurements Database, Environmental Measurements Laboratory, Office of 
Environmental Management, United States Department of Energy. 
http://www.eml.doe.govidatabases/fallout/fallout_data_search.htm  
Closed circles represent the level of Se ° Fallout during the individual calendar months of the year. 
130 
Figure 6.2 	Representative examples of RET/PTC1 analysis 
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Figure 6.3 	Birth year distribution of ret/PTC positive PTC 
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Chapter 7 
Heritable susceptibility to papillary carcinoma of the thyroid 
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PROLOGUE 
The key questions addressed by this chapter are: 
1 	Does heritable susceptibility contribute to the incidence of PTC in Tasmania? 
2 	What is the inheritance pattern of familial PTC? 
Presentations and publications arising from this Chapter: 
Published 
Burgess JR, Wilkinson R, Ware R, Greenaway TM, Percival J, Hoffman L. Two 
families with an autosomal dominant inheritance pattern for papillary carcinoma of the 
thyroid. I. Clin. Endocrinol. Metab. 1997; 82: 345-348. 
In accordance with the criteria for submission of thesis by previously published research, 
Chapter 7 is based on the above cited publication. 
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Aim 
To assess the prevalence and inheritance pattern of familial PTC in Tasmania 
Hypothesis 
1 	Germ line mutations modulate the risk for developing PTC. 
2 	A founder effect does not account for the relatively high incidence of PTC in 
Tasmania. 
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Introduction 
Understanding the role of germline mutations in modulating PTC risk is of interest for 
numerous reasons. It opens an avenue for understanding the pathogenesis of PTC, as 
well as influencing clinical management decisions (159). Familial diseases arising in 
founder populations also have the potential to influence apparent disease incidence rates 
when families are large, multigenerational, and reside in stable and relatively isolated 
communities. In Tasmania for example, two key founder mutations predisposing to 
Multiple Endocrine Neoplasia Type 1 (MEN 1), have resulted in a prevalence of MEN 1 
in Tasmania which is 5-10 fold higher than that reported for other populations (240). 
Studies assessing the prevalence of familial forms of PTC indicate that 3.5-6.2% of 
patients with PTC have one or more first degree relatives with TC (155, 241, 242). An 
association is known to exist between familial adenomatous polyposis (FAP) and 
PTC(220, 243, 244). However, a number of reports also describe families in which PTC 
occurs as a distinct entity, unrelated to FAP(155, 241, 242, 245, 246). The majority of 
such kindreds contain fewer than four family members affected by PTC. 
It is possible that either environmental factors or random association explains the 
occurrence of PTC in a proportion of these families. However some authors have 
postulated an autosomal dominant basis for familial PTC (155, 241, 245). Stoffer et al. 
also noted an increased occurrence of nonmalignant thyroid disease in some families 
with PTC, but the relationship between benign thyroid disease and the subsequent 
development of malignant papillary lesions was unclear(241). In this chapter, the 
prevalence and inheritance pattern of PTC in Tasmania is evaluated. 
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Subjects and Methods 
Following approval of the Royal Hobart Hospital Human Research Ethics Committee, all 
patients identified by the Tasmanian Cancer Registry with a diagnosis of PTC during the 
period 1978-1998 (n=180, Female:Ma1e=3.5, Age at diagnosis 46.4±1.1) were sought to 
determine the prevalence of familial PTC. Of these, 99 patients (Female:Ma1e=4.8, Age 
at diagnosis 44.5±1.0) were living, contactable and consented to provide this 
information. 
Two large Tasmanian kindreds with a family history of PTC were evaluated in detail. 
Where available, the results of isotope imaging and thyroid histopathology of tissue from 
fine needle aspiration (FNA) or surgery have been reviewed. A firm diagnosis of PTC 
could be made in those patients with characteristic histopathology. 
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Results 
In total, 99 PTC patients (male 18, female 81) living, contactable and responded the 
survey. A family history of TC was reported by 14 (14.1%). Of these, seven respondents 
belonged to two multigenerational PTC pedigrees that are described in detail below. 
Pedigree 1 
A 62-yr-old female presented with a hoarse voice. A multinodular goiter (MNG) had 
been noted 2 yr previously. On examination, left vocal cord paralysis and a hard, left 
sided neck mass were detected. Neck exploration demonstrated locally invasive papillary 
carcinoma of the thyroid. The patient was treated with total thyroidectomy and 6000 
MBq of radio iodine. No evidence of abnormal 1311 uptake was noted on post-ablative 
whole body scans. Abnormal areas of thallium uptake in the neck and chest were noted, 
becoming less prominent on consecutive scans. She remains well. 
Three of the patient's six children presented with MNG in the ensuing six months 
(Patients M, N, and P, Figure 7.1) and underwent surgical resection. Surgical 
management was undertaken because of mild compressive symptoms, a low thyrotropin 
level (indicating unsuitability for thyroxine suppression), or patient anxiety. One patient 
had FNA of the thyroid preoperatively that was nondiagnostic. PTC was detected during 
pathological examination in all cases, one microscopic, one 10 mm in diameter, and the 
other a multifocal PTC. On screening, one of the patient's six children (Patient 0) had a 
solitary nodule confirmed as PTC on excision. Screening other family members yielded 
two further relatives with MNG who had multifocal PTC (Patients U and W). Patient U 
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had evidence of malignancy on preoperative FNA. Other relatives with abnormal thyroid 
glands on screening are shown in Figure 7.1. 
The family history revealed two additional relatives who had probable thyroid carcinoma 
(patients B and D). Both had thyroidectomies in their 50's (before 1950) and were 
reported by relatives and medical practitioners to have thyroid cancer; however, 
histological confirmation was not possible. There was no family history of colonic 
malignancy or intestinal polyposis and no history of radiation exposure. 
Pedigree II 
A 49-yr-old male presented with a 3-week history of left-sided neck swelling. 
Examination revealed a 1.5 cm mass palpable in the left lobe of the thyroid gland. The 
patient's family history was unremarkable for thyroid or bowel malignancy, and there 
was no history of radiation exposure. Following ultrasound and isotope imaging (Figure 
7.1), the patient underwent hemithyroidectomy, and histopathological examination 
revealed papillary carcinoma. Total thyroidectomy was subsequently performed, and the 
patient received a 6000 MBq dose of radio iodine. Follow-up studies to 3 yr have not 
demonstrated disease recurrence. One year subsequent to presentation of the index case, 
the patient's monozygotic twin brother presented with a neck mass, assessment of which 
also revealed PTC, metastatic to a cervical lymph node. In 1995, the 23-yr-old daughter 
(Patient K) of the index case presented with a right sided thyroid mass, subsequently 
proven to be an invasive 12 mm PTC. She was treated by total thyroidectomy, ablative 
radio iodine, and thyroxine suppression. The 22-yr-old daughter of the other twin (Patient 
L) had a MNG on screening, and a sclerosing papillary microcarcinoma was found on 
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resection. There has been no evidence of recurrence in any of these family members. The 
family tree for Pedigree II is also summarized in Figure 7.1. The characteristics of 
surgically treated thyroid disease from both pedigrees are summarized in Table 7.1. 
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Discussion 
Familial PTC is relatively uncommon in Tasmania, exhibiting a prevalence (14.1%). 
Reports by other authors indicate a prevalence in the general population of approximately 
5%. The higher prevalence in my study may in part reflect a founder effect associated 
with pedigree I and II, as well as bias due to a relatively low survey response rate of 55%. 
However, the kindreds presented herein support the existence of an autosomal dominant 
inheritance pattern for PTC, separate from the established association with FAP(151). 
Pedigree I represents one of the largest kindred with non-FAP familial PTC described 
thus far. 
In both families, history and physical examination consistent with FAP or Cowden's 
syndrome was absent. Although Pedigree II is less extensive, the development of PTC in 
monozygotic twins (within one year of each other) and in two of their offspring suggests 
an underlying genetic predisposition to thyroid neoplasia. The fact that both parents and a 
grandparent of the twins lived to an advanced age without evidence of thyroid cancer 
suggests the possibility of a de novo mutation occurring early in the twin's 
embryogenesis. 
An association may exist between multinodular goitre and PTC. Existing evidence does 
not exclude this possibility, as thyroid malignancy is thought to be a multi-step process. 
Furthermore, common genetic factors have been implicated in the pathogenesis of both 
MNG and PTC (46, 49, 159, 245). It is also possible that the association is indirect, as 
the presence of MNG is likely to increase the likelihood of diagnosing "occult" 
PTC(210). However, the clinically significant extent of the majority of tumours 
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diagnosed in the families described in this study indicates this is not the dominant 
explanation. 
Incomplete penetrance of familial PTC may explain both the obligatory carrier status of 
patient C in Pedigree I and non-expression of clinically overt thyroid disease. The 
influence of secondary modifying factors, such as gender may contribute to this, as was 
the case in pedigree I, where six of seven patients with PTC are female. This observation 
is similar to that of Lote et al, who described a female predilection for FTC in a 
Norwegian family(245). Both families included individuals with multifocal FTC 
occurring at a young age, consistent with other reports of familial PTC(159, 247). 
The optimal strategy for investigation and management of kindreds with PTC is unclear. 
Exclusion of undiagnosed FAP would seem prudent, however in the absence of a family 
history of bowel malignancy, or characteristic physical stigmata of Gardner's syndrome, 
routine colonic assessment would seem unwarranted. The relatively high risk of PTC 
developing in an underlying MNG, and the limited value of ultrasonography, isotope 
scanning, and FNAB in excluding malignancy in the setting of multinodularity, argues 
strongly for thyroidectomy in family members of high risk pedigrees who have evidence 
of MNG. The screening strategy currently recommended for these families is periodic 
thyroid ultrasonography and neck palpation by an experienced examiner(160). Patients 
with evidence of goiter may then be counseled regarding the potential risk of malignancy 
and offered the option of early thyroidectomy(160). 
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Conclusions 
Prior to publication of the paper presented in this chapter, there was limited data 
available in relation to high penetrance genes associated with autosomal dominant PTC. 
Careful characterisation of families expressing such patterns of PTC inheritance should 
result in identification of susceptibility loci for PTC. The large pedigree (Pedigree I) 
described in this report provided support for the presence of a distinct autosomal 
dominant form of PTC as well as being the substrate for subsequent genomic localisation 
studies. Whilst a specific gene is yet to be identified, and familial PTC may arise from a 
number of distinct genetic loci, the observations reported herein provide impetus for 
further research. 
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Table 7.1. Thyroid gland characteristics in patients treated by thyroidectomy 
'atient Age Ultrasonography; Characteristics on isotope imaging; Thyroid histopathology 
(G) 	43 	Enlarged gland, heterogenous, consistent with MNG; MNG with lymphocytic thyroiditis. No evidence of malignancy 
(K) 62 	Enlarged nodular gland, consistent with MNG; no dominant nodule; follicular variant of PTC occurring in a MNG 
(L) 34 	3 x 2.2 cm solitary solid nodule, cold nodule in otherwise normal gland; MNG with benign dominant nodule 
(M) 35 
	
	Multiple solid and cystic nodules, consistent with MNG; overall uptake increased; dominant nodule with 
cold areas sclerosing PTC occurring in a MNG 
(N) 24 	Enlarged gland, 4 nodules; Multifocal PTC 
(0) 	42 	Solid nodule; PTC 
(P) 	39 	Consistent with MNG; overall uptake increased; no dominant cold nodule; sclerosing PTC occurring in a MNG; 
background of lymphocytic thyroiditis 
(T) 	58 	MNG 
(T1) 29 	MNG 
(T2) 26 	2 thyroid nodules, largest 2 cm MNG with lymphocytic thyroiditis 
(U) 	54 	2 thyroid nodules; left lobes; atypical cells on FNA early MNG with multifocal PTC containing follicular variants 
(V) 	32 	2 nodules left lobe early MNG 
(W) 	23 	Multiple nodules, 2-5 mm MNG; multifocal PTC in left lobe 
(Z) 	27 	MNG 
I (G) 	51 	Right lobe enlarged and homogenous, left enlarged; MNG, largest nodule 2 cm large cold area left lobe; 
generalized patchy uptake well differentiated PTC metastatic to cervical lymph node; solitary follicular adenoma in 
thyroid gland 
I (H) 	49 	Enlarged gland; nodular left lobe containing a 20 mm solid nodule with patchy tracer uptake consistent with MNG 
'TC containing follicular elements 
I (K) 	23 	Normal sized gland containing 10 mm and 2 mm cold nodules; PTC containing follicular elements 
I (L) 	22 	Lesions in upper left lobe and heterogeneous texture lower pole right lobe normal sized gland, areas of marked 
decrease in uptake sclerosing papillary microcarcinoma 
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PEDIGREE II 
A 	8 
Figure 7.1 Pedigree charts for family I and II 
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Conclusion and Future Studies 
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Thesis Conclusions 
This thesis provides the first comprehensive evaluation of TC incidence trends in 
Australia. Furthermore, the Tasmanian population proved to be a suitable model for 
evaluating the factors underlying contemporary TC incidence patterns. 
A review of notifications to Australian Cancer Registries during the last two decades of 
the twentieth century demonstrated a progressive rise in the reported incidence of TC. 
The most pronounced increase occurred during the 1990's and was attributable to an 
increasing incidence of PTC. The geographic pattern for this trend was most evident in 
Australia's eastern seaboard States, namely Tasmania, Victoria, New South Wales and 
Queensland. This distribution co-localised with the ecological pattern of iodine 
deficiency in Australia. The population of the Australian south-eastern seaboard was 
mild-moderately iodine deficient prior to introduction of iodine-based disinfectants 
(iodophors) by the dairy industry in the 1960's. The residual iodine content in milk 
(related to iodophor use) serendipitously corrected the deficiency. Progressive phase-out 
of these disinfectants in the late 1980's has been associated with a nationwide decline in 
iodine nutrition. Over the past decade the population of much of Australia's eastern 
seaboard has become iodine deficient. Tasmania, recognised as has having the lowest 
pre-odophor level of iodine nutrition and highest prevalence of endemic goitre, 
experienced the greatest rise in PTC incidence of all the Australian commonwealth. 
However, the information available from the national TC dataset was insufficient to 
clarify the role of Cancer Registry ascertainment bias, changing trends in medical 
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practice and altered patterns of PTC risk factor exposure. Addressing these issues 
required detailed evaluation of a representative population. The Tasmania community 
was selected for this purpose. 
Detailed validation of Tasmanian Cancer Registry case ascertainment was undertaken. 
This indicated PTC registration was 93.9% complete and without evidence of significant 
temporal distortion. As this assessment included the period during which PTC incidence 
doubled, I was able to exclude biased Cancer Registry case ascertainment as an 
explanation for the observed rise in PTC incidence. This was an important consideration, 
as prior to this study, time related variation in case ascertainment by cancer registries had 
been postulated as making an important contribution to observed PTC trends. 
Furthermore, the morphological classification of tumours over time was found to be 
stable when independently reviewed. Changes in tumour classification did not account 
for observed trends in TC incidence. 
The dominant change identified by this study was a significant increase in diagnosis of 
small PTC (<1cm in maximum dimension). Iodine supplementation of iodine deficient 
communities has been associated elsewhere with increased diagnosis of PTC of smaller 
size and earlier stage. Therefore, given the previously identified geographic linkage 
between increased PTC incidence and the distribution of historical iodine deficiency in 
Australia, further evaluation of the potential impact changing iodine nutrition on PTC 
incidence and pathogenesis was undertaken. 
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Despite two decades of documented iodine sufficiency in Tasmania, PTC incidence 
increased more than two-fold at the time when iodine deficiency recurred. Whilst not 
excluding a long latency linking improved iodine nutrition in the 1960's to increased 
PTC in the 1990's, such a relationship appears unlikely and inconsistent with the 
expected time course associated with the concept of "papillarisation" following iodine 
supplementation. 
A non-biological association between community iodine supplementation occurring in 
conjunction with improved community screening for thyroid disease (increasing 
availability of ultrasonography and consequential interventions such as FNAB and 
thyroid surgery), appears to be a more plausible link between iodine nutrition and 
increased incidence of PTC. Similarly, the progressive improvement in medical care and 
technology occurring in recent decades could similarly increase the diagnosis of "occult" 
PTC. 
A survey and ultrasonographic study was undertaken to determine the prevalence of 
subclinical and previously diagnosed thyroid disease in Tasmania. The data presented in 
Chapter 5 indicate a divergence between the absolute risk for nodular thyroid disease (as 
evidenced by ultrasonography) versus the likelihood of clinically diagnosed and treated 
thyroid disease. The former was common, irrespective of birth place and residence, 
whilst the latter was relatively associated with prolonged residence in Tasmania during 
the era of iodine deficiency. The failure to observe a significant association between 
place of birth and TC suggests a unique environmental modifier is unlikely to account for 
PTC incidence trends in Tasmania. 
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However, the findings were consistent with historically more severe iodine deficiency in 
Tasmania increasing the prevalence of benign goiter and thyroid dysfunction. Evaluation 
of these may have secondarily increased the likelihood of diagnosing "occult" PTC. 
Moreover, thyroid ultrasonography in any person without clinical suspicion of thyroid 
disease (irrespective of their iodine nutritional history) may also considered a "risk 
factor" for FNAB, thyroid surgery and consequently the diagnosis of "occult" PTC. 
My results suggested the increase in PTC incidence observed in Tasmania and more 
widely may in large part be attributable to greater diagnosis of small PTC, many of which 
are likely to have been asymptomatic, identified by neck ultrasonography and subsequent 
FNAB. Iodine deficient (or previously deficient) populations can be expected to have an 
higher prevalence of goitre and larger thyroid nodules. The higher prevalence of 
clinically apparent structural thyroid disease is likely to increase thyroid imaging, FNAB 
and consequently the diagnosis of "occult" PTC. Past and present iodine nutrition need 
have no causal link with PTC pathogenesis, merely serve to modify incidental 
recognition of existing subclinical nodular thyroid disease. 
However, it was also noted that the incidence of PTC larger than lcm in patients without 
history of preoperative FNAB had increased in Tasmania, suggesting the occurrence of 
clinically relevant tumours increased. It was important therefore to examine trends for 
exposure to established risk factors such as ionising radiation. In the absence of case 
specific exposure data for fallout to confirm this, Chapter 6 sought to use the RET/PTC1 
rearrangement as a surrogate marker for the involvement of ionising radiation in the 
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pathogenesis of individual PTC. Observational studies have suggested the RET/PTC1 
rearrangement may occur at higher frequency in PTC arising following thyroidal 
irradiation. 
I was able to map trends for the prevalence of RET/PTC1 relative to incidence trends for 
PTC. Whilst the RET/PTC1 mutation was frequently identified in Tasmanian PTC, there 
was no clear relationship between RET/PTC1 and recent PTC incidence trends. This can 
be interpreted as either a negative finding (in as much as the fraction of PTC with 
RET/PTC1 rearrangement failed to increase significantly in parallel with the rise in 
overall PTC incidence) or conversely, suggestive of a proportional and increasing 
contribution of ionising radiation to PTC diagnosed in Tasmania. Future research might 
address this question by undertaking appropriately powered longitudinal studies 
evaluating populations before and after a documented exposure to fallout. 
I also examined the prevalence and genetic basis of familial PTC. A founder effect 
combined with screening did not account for the rise in PTC incidence observed in 
Tasmania. The large Tasmanian pedigree described in Chapter 7 provided support for 
the presence of a distinct autosomal dominant form of PTC as well as a basis for 
subsequent genomic localisation studies. Whilst a specific gene is yet to be identified, 
and familial FTC may arise from a number of distinct genetic loci, this manuscript 
provided impetus for further research. 
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In summary, this thesis addressed the questions posed in Chapter 1 and reached the 
following conclusions: 
1 The incidence of TC increased in Australia during the last two decades of the 
twentieth century due to a rise in incidence of PTC. 
2 Geographic variation for PTC incidence in Australia was evident, with the 
greatest increase occurring in the south-eastern States of Tasmania, Victoria and 
NSW. 
3 The Tasmanian population proved to be a suitable model for evaluating the basis 
for PTC incidence trends given its stable population structure, well documented 
history of iodine nutrition and stable health care system. 
4 There was no evidence of any substantial systematic modification to 
histopathological diagnostic criteria or Cancer Registry case ascertainment and 
registration protocols to explain observed PTC incidence trends. 
5 Whilst the incidence of both large and small PTC increased over the study period, 
greater diagnosis of PTC<1 cm diameter was the dominant factor accounting for 
the rise in PTC incidence. Increasing use of neck imaging and FNAB in patients 
with asymptomatic nodular thyroid appear to be the main antecedent factors 
driving this trend. 
6 The geographic patterns for PTC incidence trends were compatible with historical 
and contemporary patterns of iodine deficiency in Australia. The severity of 
historical deficiency mapped proportionally with the magnitude of recent PTC 
incidence increases. 
7 \ I cannot exclude a direct biological influence of iodine nutrition on PTC 
pathogenesis, however, the influence of improving and subsequently declining 
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levels of iodine nutrition in Tasmania over the past four decades appears to have 
been minimal in comparison to the dominant influence of increasing use of neck 
ultrasonography and FNAB resulting in diagnosis of "occult" PTC. 
8 No direct evidence to support ionising radiation in the genesis of contemporary 
PTC incidence trends has been identified. However, the finding of RET/PTC1 
mutation as highly prevalent in Tasmanian PTC cases warrants further 
consideration of this possibility. 
9 Autosomal dominant susceptibility to PTC has been identified in a small 
proportion of Tasmanian PTC cases, however the impact of familial disease has 
been relatively minimal on overall PTC incidence trends. 
10 Based on the data presented in this thesis, it is possible to estimate the relative 
contributions of ascertainment bias, and changes in underlying biological 
incidence in contemporary PTC incidence trends. Increased ascertainment of 
"occult" PTC due to greater use of sensitive neck imaging and contemporary 
thyroid nodule evaluation paradigms explains the majority of increased PTC 
diagnoses during the 1990's, whilst a biologically significant increase in 
underlying PTC incidence appears responsible for the remainder. 
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Future Studies 
1 
	
Follow-up of Tasmanian PTC incidence trends in association with 
utilization profiles for neck imaging and FNAB to determine if a stable 
PTC incidence pattern is established consistent with contemporary 
imaging usage. 
2 
	 An intervention study based on structured medical practitioner education 
regarding appropriate use of thyroid ultrasonography to determine if 
decreased non-specific neck imaging is associated with reduced PTC 
incidence. 
3 
	
A large-scale Australian national study, sufficiently powered to assess the 
impact of changes to national iodine nutrition on PTC incidence. 
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